Materials, methods, and systems for cellular expansion of gamma delta t-cells

Abstract

Provided is a serum-free, xeno-free, feeder-free method for selectively activating and expanding human γδ T cells to achieve sufficient cell numbers for adoptive cell therapy while retaining their robust intrinsic antitumor activity comprising: (a) contacting the γδ T cells with an isolated antibody or antigen-binding fragment that agonizes the γδ T cell receptor; (b) culturing the γδ T cells in cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-22, IL-27, and TGFβ, and combinations thereof; wherein the cell culture medium further comprises a serum substitute In some embodiments, the γδ T cells are obtained from induced pluripotent stem cells (iPSCs) and / or peripheral blood mononuclear cells (PBMCs). In further embodiments, the γδ T cells express the Vγ9Vδ2 T cell receptor. The iPSC-derived γδ T cells or the PBMC-derived γδ T cells may be engineered to express a chimeric antigen receptor (CAR).

Description

ATTORNEY DOCKET NO. JBI6882WOPCT1MATERIALS, METHODS, AND SYSTEMS FOR CELLULAR EXPANSION CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This Application claims the benefit of U.S. Provisional Applications 63 / 641,288, filed on May 1, 2024; 63 / 641,301, filed on May 1, 2024; 63 / 717,757, filed on November 7, 2024 and 63 / 717,767, filed on November 7, 2024, which are hereby incorporated by reference in their entirety. REFERENCE TO A SEQUENCE LISTING SUBMITTED IN XML FORMAT

[0002] The present application hereby incorporates by reference the entire contents of the Sequence Listing contained in the XML file named JBI6882WOPCT1_SL.xml” which was created on March 27, 2025, and is 659,222 bytes in size. FIELD

[0003] Materials and methods for cellular expansion, including the field of cellular expansion and more particularly to serum-free, xeno-free, and feeder-free methods for selectively activating and expanding human γδ T cells to achieve sufficient cell numbers for adoptive cell therapy while retaining their robust intrinsic antitumor activity. BACKGROUND

[0004] T cell immunotherapy, such as autologous chimeric antigen receptor (CAR) T cells, has been reported to be efficacious therapy for the treatment of some cancers, such as hematologic malignancies; however, applications of cell therapy to treat various cancer types have met numerous and varied challenges. SUMMARY

[0005] Advances in T cell immunotherapy have been reported, such as in autologous CAR T cell therapy; however, applications of cell therapy to treat various cancer types have unmet challenges and the present invention, against this backdrop, meets many of these challenges impeding access to therapeutic cell products, such as prohibitive, high manufacturing costs, increased complexity, lack of a consistent and scalable manufacturing process, etc. For example, the inventors of the present disclosure use induced pluripotent stem cells (iPSCs), which can undergo inter alia self-renewal, gene editing, multilineage differentiation, etc., to advance off-the-shelf, allogeneic, CAR-engineered T cell therapy platforms with more commercially viable, automated, energy efficient, and resource sparing manufacturingATTORNEY DOCKET NO. JBI6882WOPCT1 processes. For example, an iPSC-derived cell therapy platform can be based on γδ T cells, which possess intrinsic antitumor activity and whose tumor infiltration is associated with favorable outcomes.

[0006] iPSC-derived γδ T cells (iγδ T cells) can be used as an off-the-shelf, allogeneic, CAR- engineered T cell therapy product, but serum-free, xeno-free, and feeder-free expansion methods are needed that produce iγδ T cells in sufficient numbers to dose many patients and that retain their robust intrinsic antitumor activity.

[0007] Provided herein are serum-free, xeno-free, and feeder-free methods for activating and expanding γδ T cells derived from induced pluripotent stem cells (iPSCs), known as iPSC- derived γδ T cells (iγδ T cells), and / or for expanding γδ T cells derived from peripheral blood mononuclear cells (PBMCs).

[0008] Provided is a serum-free, xeno-free, and feeder-free method for selectively activating and expanding human γδ T cells comprising: (a) contacting the γδ T cells with an isolated antibody or antigen-binding fragment; (b) culturing the γδ T cells in cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-22, IL-27, and TGFβ, and combinations thereof; wherein the cell culture medium further comprises a serum substitute. In some embodiments, the γδ T cells are in contact with the isolated antibody or antigen binding fragment in step (a) but not in step (b). In some embodiments, step (a) occurs in cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-22, IL-27, and TGFβ and combinations thereof; wherein the cell culture medium further comprises a serum substitute.

[0009] In some embodiments, the γδ T cells are derived from iPSCs and / or from PBMCs. In further embodiments, the γδ T cells express the Vγ9Vδ2 T cell receptor (TCR).

[0010] In some embodiments, the isolated antibody or antigen-binding fragment in step (a) binds to a region of the TCRγδ heterodimer.

[0011] In further embodiments, the iγδ T cells are engineered to express a chimeric antigen receptor (CAR) or the PBMC-derived γδ T cells are engineered to express a CAR. The iPSC- derived γδ T cells and / or the PBMC-derived γδ T cells may be engineered to express a CAR prior to activation and expansion.

[0012] The iPSC-derived γδ T cells and / or the PBMC-derived γδ T cells may be engineered to express a CAR prior to step (a).

[0013] The iPSC-derived γδ T cells and / or the PBMC-derived γδ T cells may be engineered to express a CAR after step (a).ATTORNEY DOCKET NO. JBI6882WOPCT1

[0014] The iPSC-derived γδ T cells may be engineered to express a CAR prior to step (a) or the PBMC-derived γδ T cells may be engineered to express a CAR after step (a).

[0015] In some embodiments, the CAR-engineered T cells are exposed to cell culture medium comprising IL-21 and IL-15 for 2 days.

[0016] In some embodiments, the isolated antibody or antigen-binding fragment binds to the Vγ9, Vδ2, Cγ1, Cγ2 or Cδ domain of the TCRγδ heterodimer and acts as a TCR agonist and triggers TCR-coupled signaling pathways leading to T cell activation.

[0017] In some embodiments, the isolated antibody or antigen-binding fragment is fully human or humanized.

[0018] In some embodiments, the serum substitute is Cell-ViveTMT-NK xeno-free serum substitute.

[0019] In some embodiments, the serum substitute has a concentration of 5% to 10%. In further embodiments, the serum substitute concentration is 10%.

[0020] In some embodiments, the isolated antibody or antigen-binding fragment has a concentration of about 0.5 to about 10 µg / mL. In further embodiments, the isolated antibody or antigen-binding fragment has a concentration of 2.5 µg / mL.

[0021] In some embodiments, the contacting of γδ T cells with an isolated antibody or antigen-binding fragment has a duration of about 0.5 to about 3 days. In further embodiments, the contacting of γδ T cells with an isolated antibody or antigen-binding fragment has a duration of about 0.5, 1, 1.5, 2, 2.5, or 3, or days.

[0022] In some embodiments, the contacting the γδ T cells with an isolated antibody or antigen-binding fragment has a duration of 2 days.

[0023] In some embodiments, the γδ T cells are seeded in step (a) at about 0.1 x 106cells / mL to about 1.0 x 106cells / mL upon initial seeding onto the antibody or antigen-binding fragment. In further embodiments, the γδ T cells are seeded at 0.5 x 106cells / mL upon initial seeding onto the antibody or antigen-binding fragment.

[0024] In some embodiments, the γδ T cells are seeded in step (b) at intervals in descending cell concentration of about 10 x 106cells / mL to about 0.1 x 106cells / mL in cell culture medium. In further embodiments, the γδ T cells are seeded at intervals in descending concentration of 0.5 x 106cells / mL to 0.1 x 106cells / mL.

[0025] In some embodiments, the γδ T cells are contacted with the isolated antibody or antigen-binding fragment on Day 0. The γδ T cells are transferred to new culture vessels on Days 2, 6 and 8 and are cultured following a descending seeding density scheme where cellATTORNEY DOCKET NO. JBI6882WOPCT1 densities are 0.5 x 106cells / mL on Days 0 to 3 and decrease to 0.25 x 106cells / mL on Days 3 to 8 and then to 0.1 x 106cells / mL on Days 8 to 14. In further embodiments, additional volumes of fresh complete expansion medium are added to cultures on Days 3 and 10.

[0026] In some embodiments, the isolated antibody or antibody fragment is listed in any of Tables 1-7 or is derived from an antibody or antibody fragment listed in any of Tables 1-7. In further embodiments, the isolated antibody is VG9B1244, VG9B1254, VG9B1348 or VG9B1701. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] FIGS.1A-1B illustrate HDX-MS epitope mapping results. FIG.1A: 3D ribbon diagram shows location of variable and constant domains of the TCRγ or TCRδ chain in the TCRγδ heterodimer. FIG.1B: Epitope mapping identified the 4 lead TCR agonistic mAbs as Vγ9 or Vδ2 binders. The figure shows HDX-MS epitope mapping of mAb clones VG9B1244, VG9B1254, VG9B1348 and VG9B1701 overlaid onto the X-ray crystal structure of Vγ9Vδ2 TCR heterodimer (G115) fused to the human Fc domain (huFc).

[0028] FIGS.2A-2B demonstrate that increasing the percentage of serum substitute in the cell culture medium increases cell viability and cell expansion. FIG.2A shows that increasing the percentage of Cell-ViveTMT-NK Xeno-Free serum substitute in Immunocult™-XF medium to 10% from the recommended 5% improves iγδ T cell viability. FIG.2B shows that increasing the percentage of Cell-ViveTMT-NK Xeno-Free serum substitute in Immunocult™-XF medium to 10% from the recommended 5% improves expansion of iγδ T cells derived from Clones 1 and 2 (iγδ T cells were expanded with VG9B1701 mAb).

[0029] FIGS.3A-3B demonstrate that frequency of medium changes affects cell viability. FIG.3A illustrates development of the cell seeding, splitting and feed schedule for iγδ T cells. In Scheme 1, iγδ T cells were subjected to substantial (5X) yet rare (3X) medium volume increases within 14-day expansion. In Scheme 2, iγδ T cells were subjected to frequent medium changes (5X), while maintaining high cell density. FIG.3B shows that Scheme 1 yielded overall higher viability than Scheme 2.

[0030] FIGS.4A-4B demonstrate that cell seeding density throughout the culture process affects cell viability and expansion. FIG.4A illustrates optimization of seeding and cell concentration of iγδ T cells derived from Clone 1. Results show that iγδ T cell seeding density affects viability. A seeding density of 0.5x106 / mL results in optimal viability. FIG. 4B demonstrates that using a descending cell density going from 0.5x106 / mL on Day 0, toATTORNEY DOCKET NO. JBI6882WOPCT1 0.25x106 / mL on Day 3, to 0.1x106 / mL on Day 8 improves viability and expansion as compared to constant seeding density of 0.5x106 / mL.

[0031] FIGS.5A-5B demonstrate that the expansion protocol using the VG9B1348 mAb selectively activates and expands primary Vγ9Vδ2 T cells derived from peripheral blood. FIG.5A shows selective activation and expansion of expanded Vγ9Vδ2 T cells. Prior to expansion (Day 0), enriched PBMC-derived γδ T cells were 68% CD3+Vγ9+Vδ2+ for Donor 1 and 35% CD3+Vγ9+Vδ2+ for Donor 2, respectively. At Day 14, total purity of expanded Vγ9Vδ2 T cell population reached 98% and 95% for Donor 1 and Donor 2, respectively, highlighting selective expansion of the Vγ9Vδ2 T cell subset. FIG.5B demonstrates expansion kinetics of enriched PBMC-derived γδ T cells from the two donors.

[0032] FIGS.6A-6E show expansion summary for iγδ T cells derived from Clone 1. High viability (FIG.6A) and high purity (FIG.6B) of iγδ T cells were observed post-expansion. Higher fold expansions per iγδ T cell input (FIG.6C), per iCD34 input (FIG.6D), and per iPSC input (FIG.6E) were observed when VG9B1348 and VG9B1701 mAbs were used than when VG9B1244 and VG9B1254 mAbs were used to expand Clone 1-derived iγδ T cells.

[0033] FIGS.7A-7E show expansion summary for iγδ T cells derived from Clone 2. High viability (FIG.7A) and high purity (FIG.7B) of iγδ T cells were observed post-expansion. Higher fold expansion per iγδ T cell input (FIG.7C), per iCD34 input (FIG.7D), and per iPSC input (FIG.7E) was observed when VG9B1348 mAb was used than when VG9B1244, VG9B1254 and VG9B1701 mAbs were used to expand Clone 2-derived iγδ T cells.

[0034] FIGS.8A-8B demonstrate that expanded iγδ T cells exhibit a similar surface phenotype. FIG.8A shows that iγδ T cells derived from two distinct clones, Clones 1 and 2 (which were derived from different donors), exhibit distinct surface phenotypes prior to expansion (Day 0). FIG.8B shows that iγδ T cells derived from Clones 1 and 2 have similar surface phenotypes post-expansion on Day 14, highlighting that the methods described herein can be used to activate and expand iγδ T cells resembling similar phenotypic profile regardless of source of starting material.

[0035] FIGS.9A-9E show the viability, purity, and fold expansion of iγδ T cells, which were redifferentiated from multiple iCD34 sources and which were activated and expanded using the present invention. Notably, the expansion protocol presented in the current invention yields viable (FIG.9A) and pure (FIG.9B) iγδ T cells derived from iCD34 cells redifferentiated in 2D or 3D formats and harvested from different fractions within each format (single cell or cluster fraction in 3D format, and adherent or non-adherent fraction in 2D format). The highest fold expansion per input iγδ T cell (FIG.9C) was observed for iγδ TATTORNEY DOCKET NO. JBI6882WOPCT1 cells derived from iCD34s in the 3D cluster fraction. Overall highest fold expansions per input iCD34 and iPSC (FIG.9D and FIG.9E, respectively), however, were observed for iγδ T cells derived from iCD34s in the 2D adherent fraction.

[0036] FIGS.10A-10D show long-term cytotoxic potentials of expanded iγδ T cells in a 3D spheroid assay. Cytotoxic potentials of expanded iγδ T cells based on iCD34 cells source, specifically 2D non-adherent fraction (FIG.10A), 2D adherent fraction (FIG.10B), 3D single cell fraction (FIG.10C), and 2D cluster fraction (FIG.10D). Zoledronate (ZOL)-expanded primary γδ T cells were used as a comparator. Expanded γδ T cells were co-cultured with the HepG2 target tumor cell line-derived spheroids at a 1:1 effector to target ratio. iγδ T cells demonstrate more robust cytotoxicity than ZOL-expanded primary γδ T cells. All expanded iγδ T cells, irrespective of the iCD34 redifferentiation format and of the agonistic mAb used, exhibit durable tumor cell killing in the 3D spheroid cytotoxicity assay.

[0037] FIGS.11A-11C show effects of the duration of IL-21 and IL-15 signaling on the expansion potentials of unengineered and CAR-engineered iγδ T cells. FIG.11A shows the cytokine supplementation scheme evaluated on unengineered and CAR-engineered iγδ T cells. IL-21 and IL-15 were added to the expansion medium for 2, 7 or 14 days of the expansion process. Following the specified exposure time, the IL-21 and IL-15 cytokine cocktail was replaced with an IL-2 and IL-15 cytokine cocktail (as in the original standard operating procedure (SOP) outlined in Example 4) when IL-21 and IL-15 were added for the first 2 or 7 days. FIG.11B shows expansion outcomes in unengineered iγδ T cells following exposure to IL-21 and IL-15 at IL-21 concentrations of 1, 10 or 40 ng / mL for 2, 7 and 14 days. Unengineered iγδ T cells expanded in the presence of IL-21 and IL-15 exhibit decreased expansion efficiency as compared to unengineered iγδ T cells expanded under SOP conditions, with decreasing expansion observed with higher concentrations and prolonged exposure to IL-21. FIG.11C shows expansion outcomes in CAR-engineered iγδ T cells exposure to IL-21 and IL-15 at IL-21 concentrations of 1, 10 or 40 ng / mL for 2, 7 and 14 days. CAR-engineered iγδ T cells expanded in the presence of IL-21 and IL-15 exhibit improved expansion efficiency as compared to CAR-engineered iγδ T cells expanded under SOP conditions, with the highest expansion observed when IL-21 and IL-15 exposure was limited to 2 days at 10 ng / mL.

[0038] FIGS.12A-12B show the viability of unengineered and CAR-engineered iγδ T cells expanded in presence of IL-21 and IL-15. FIG.12A shows viability of unengineered iγδ T cells following exposure to IL-21 and IL-15 at IL-21 concentrations of 1, 10 or 40 ng / mL for 2, 7 and 14 days. Unengineered iγδ T cells expanded in the presence of IL-21 and IL-15ATTORNEY DOCKET NO. JBI6882WOPCT1 exhibit viability comparable to that of unengineered iγδ T cells expanded under SOP conditions. FIG.12B shows viability of CAR-engineered iγδ T cells following exposure IL- 21 and IL-15 at IL-21 concentrations of 1, 10 or 40 ng / mL for 2, 7 and 14 days. CAR- engineered iγδ T cells expanded in the presence of IL-21 and IL-15 exhibit viability comparable to that of CAR-engineered iγδ T cells expanded under SOP conditions.

[0039] FIGS.13A-13B show iγδ T cell purity (i.e., %CD3+Vγ9+Vδ2+cells) of unengineered and CAR-engineered iγδ T cells expanded in presence of IL-21 and IL-15. FIG.13A shows iγδ T cell purity of unengineered iγδ T cells following addition of IL-21 and IL-15 at IL-21 concentrations of 1, 10 or 40 ng / mL for 2, 7 and 14 days. Unengineered iγδ T cells expanded in the presence of IL-21 and IL-15 exhibit purity comparable to that of unengineered iγδ T cells expanded under SOP procedure. FIG.13B shows purity of CAR-engineered iγδ T cells following exposure to IL-21 at concentration 1, 10 or 40 ng / mL for 2, 7 and 14 days. CAR- engineered iγδ T cells expanded in the presence of IL-21 and IL-15 exhibit decreased iγδ T cell purity compared to that of CAR-engineered iγδ T cells expanded under SOP procedure. Exposure to IL-21 and IL-15 for 2 days results in highest iγδ T cell purity.

[0040] FIG.14 shows percentages of CAR+ iγδ T cells expanded in presence of IL-21 and IL-15 at IL-21 concentrations of 1, 10 or 40 ng / mL for 2, 7 and 14 days. Exposure to IL-21 and IL-15 for 2 days results in highest purity of CAR-engineered cells. DETAILED DESCRIPTION

[0041] While the general inventive concepts are susceptible of embodiment in many forms, there are shown in the drawings, and will be described herein in detail, specific embodiments thereof with the understanding that the present disclosure is to be considered an exemplification of the principles of the general inventive concepts. Accordingly, the general inventive concepts are not intended to be limited to the specific embodiments illustrated herein.

[0042] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0043] The articles “a” and “an” are used herein to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “a cell” means one cell or more than one cell.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0044] “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±5%, preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

[0045] The terms “antibody” and "antibodies" as used herein are meant in a broad sense and include immunoglobulin molecules including polyclonal antibodies, monoclonal antibodies including, human, human-adapted, humanized and chimeric monoclonal antibodies, antibody fragments, bispecific or multispecific antibodies, dimeric, tetrameric or multimeric antibodies, and single chain antibodies.

[0046] Immunoglobulins can be assigned to five major classes, namely IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant domain amino acid sequence. IgA and IgG are further sub-classified as the isotypes IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4. Antibody light chains of any vertebrate species can be assigned to one of two clearly distinct types, namely kappa (k) and lambda (l), based on the amino acid sequences of their constant domains.

[0047] The term "antibody fragments" refers to a portion of an immunoglobulin molecule that retains the heavy chain and / or the light chain antigen binding site, such as heavy chain complementarity determining regions (HCDR) 1, 2 and 3, light chain complementarity determining regions (LCDR) 1, 2 and 3, a heavy chain variable region (VH), or a light chain variable region (VL). Antibody fragments include a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CH1 domains; a F(ab)2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; a Fd fragment consisting of the VH and CH1 domains; a Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a domain antibody (dAb) fragment, which consists of a VH domain. VH and VL domains can be engineered and linked together via a synthetic linker to form various types of single chain antibody designs where the VH / VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate single chain antibody constructs, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in PCT Intl. Publ. Nos. WO1998 / 44001, WO1988 / 01649, WO1994 / 13804, and WO1992 / 01047. These antibody fragments are obtained using well known techniques known to those of skill in the art, and the fragments are screened for utility in the same manner as are full length antibodies.

[0048] The phrase "isolated antibody" refers to an antibody or antibody fragment that is substantially free of other antibodies having different antigenic specificities (e.g., an isolatedATTORNEY DOCKET NO. JBI6882WOPCT1 antibody specifically binding CD38 is substantially free of antibodies that specifically bind antigens other than human CD38). An isolated antibody that specifically binds CD38, however, can have cross-reactivity to other antigens, such as orthologs of human CD38, such as Macaca fascicularis (cynomolgus monkey) CD38. Moreover, an isolated antibody may be substantially free of other cellular material and / or chemicals.

[0049] "Humanized antibody" refers to an antibody in which the antigen binding sites are derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Humanized antibodies may include substitutions in the framework regions so that the framework may not be an exact copy of expressed human immunoglobulin or germline gene sequences.

[0050] "Human antibody" refers to an antibody having heavy and light chain variable regions in which both the framework and the antigen binding sites are derived from sequences of human origin. If the antibody contains a constant region, the constant region also is derived from sequences of human origin. A human antibody comprises heavy or light chain variable regions that are "derived from" sequences of human origin wherein the variable regions of the antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes. Such systems include human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice carrying human immunoglobulin loci as described herein. A human antibody may also contain amino acid differences when compared to the human germline or rearranged immunoglobulin sequences due to, for example, naturally occurring somatic mutations or intentional introduction of substitutions in the framework or antigen binding sites. Typically, a human antibody is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical in amino acid sequence to an amino acid sequence encoded by a human germline or rearranged immunoglobulin gene.

[0051] Isolated humanized antibodies may be synthetic. Human antibodies, while derived from human immunoglobulin sequences, may be generated using systems such as phage display incorporating synthetic CDRs and / or synthetic frameworks, or can be subjected to in vitro mutagenesis to improve antibody properties, resulting in antibodies that do not naturally exist within the human antibody germline repertoire in vivo.

[0052] The term "recombinant antibody" as used herein, includes all antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic or transchromosomal for human immunoglobulin genes or a hybridoma prepared therefrom, antibodies isolated from a hostATTORNEY DOCKET NO. JBI6882WOPCT1 cell transformed to express the antibody, antibodies isolated from a recombinant, combinatorial antibody library, and antibodies prepared, expressed, created or isolated by any other means that involve splicing of human immunoglobulin gene sequences to other DNA sequences, sequences, or antibodies that are generated in vitro using Fab arm exchange such as bispecific antibodies.

[0053] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope, or in a case of a bispecific monoclonal antibody, a dual binding specificity to two distinct epitopes.

[0054] The term "epitope" as used herein means a portion of an antigen to which an antibody specifically binds. Epitopes usually consist of chemically active (such as polar, non-polar or hydrophobic) surface groupings of moieties such as amino acids or polysaccharide side chains and can have specific three-dimensional structural characteristics, as well as specific charge characteristics. An epitope can be composed of contiguous and / or discontiguous amino acids that form a conformational spatial unit. For a discontiguous epitope, amino acids from differing portions of the linear sequence of the antigen come in close proximity in 3- dimensional space through the folding of the protein molecule.

[0055] The term “chimeric antigen receptor” or “CAR” as used herein means a synthetic or recombinant receptor comprising an antigen specific domain, a costimulatory domain and an intracellular signaling domain. In some embodiments, the CAR further comprises an extracellular hinge or spacer region, a transmembrane domain, or combinations thereof. In some embodiments, the antigen specific domain is a scFv.

[0056] The term “chimeric antigen receptor T cell” or “CAR T” as used herein means a T cell expressing a CAR.

[0057] In some embodiments of any of the compositions or methods described herein, a range is intended to comprise every integer or fraction or value within the range.

[0058] Embodiments described herein as “comprising” one or more features may also be considered as disclosure of the corresponding embodiments “consisting of” and / or “consisting essentially of” such features.

[0059] To date, the activation and expansion of human γδ T cells, specifically Vγ9Vδ2 T cells, uses the bisphosphonate, zoledronate. Zoledronate induces accumulation of the phosphoantigens IPP and DMAPP in monocytes, and binding of these phosphoantigens to the intracellular domain of butyrophilin Subfamily 3 Member A1 (BTN3A1) results in conformational changes in the BTN3A1 / 2A1 complex, leading to subsequent recognition byATTORNEY DOCKET NO. JBI6882WOPCT1 and activation of Vγ9Vδ2 T cells. In iPSC-derived systems, monocytes (or other antigen- presenting cells) represent feeder cells, and therefore zoledronate-based expansion is not feasible for a serum-free, xeno-free, and feeder-free expansion method. Provided are methods that do not have the same limitations as previously described methods. METHODS

[0060] Provided is a serum-free, xeno-free, and feeder-free method for activating and expanding human γδ T cells comprising: (a) contacting the γδ T cells with an isolated antibody or antigen-binding fragment; (b) culturing the γδ T cells in cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-22, IL-27, and TGFβ and combinations thereof; wherein the cell culture medium further comprises a serum substitute. In some embodiments, the γδ T cells are in contact with the isolated antibody or antigen binding fragment in step (a) but not in step (b). In some embodiments, step (a) occurs in cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-22, IL-27, and TGFβ and combinations thereof; wherein the cell culture medium further comprises a serum substitute.

[0061] The expanded human γδ T cells of the embodiments described herein can be used as an off-the-shelf, allogeneic CAR-engineered T cell therapy product when expanded in sufficient cell numbers to dose many patients. The present disclosure discusses cell culture and expansion procedures that yield γδ T cells with high purity and with robust functional potential. In particular, the TCR agonistic monoclonal antibodies (mAbs) described herein are used to achieve high purity and fold expansion of iPSC-derived γδ T cells. The agonistic mAb-induced activation and expansion is performed in a serum-free, xeno-free, and feeder- free system to ensure feasibility of expansion procedures for product manufacturing, compliance with FDA regulations and clinical trials.

[0062] In some embodiments, the γδ T cells are derived from induced pluripotent stem cells (iPSCs) and / or from peripheral blood mononuclear cells (PBMCs).

[0063] The methods described herein can be used to activate and expand iγδ T cells derived from any induced CD34 positive cell (iCD34 cell) source. TCRγδ-specific Antibodies and Antigen-Binding Fragments

[0064] In some embodiments, the isolated antibody or antigen-binding fragment binds to a region of the TCRγδ heterodimer. In further embodiments, the isolated antibody or antigen- binding fragment that binds to a region of the TCRγδ heterodimer is described inATTORNEY DOCKET NO. JBI6882WOPCT1 international patent publication WO 2022093888 or in U.S. Provisional Patent Application No.63 / 515,672 filed July 26, 2023, each of which is hereby incorporated by reference in its entirety. In yet further embodiments, the isolated antibody or antigen binding fragment that binds to a region of TCRγδ heterodimer is described herein.

[0065] Described herein are isolated antibodies or antigen-binding fragments thereof that specifically bind to the TCRγδ heterodimer and that are agonistic to the γδTCR.

[0066] The general structure of an antibody molecule comprises an antigen binding domain, which includes heavy and light chains and the Fc domain, which serves a variety of functions, including complement fixation and binding antibody receptors. In some embodiments, the isolated antibodies or antigen-binding fragments antibody may specifically bind to a region of the TCRγδ heterodimer, which is a subunit of the γδTCR.

[0067] The described TCRγδ-specific antibodies or antigen-binding fragments include all isotypes, IgA, IgD, IgE, IgG and IgM, and synthetic multimers of the four-chain immunoglobulin structure. The described antibodies or antigen-binding fragments also include the IgY isotype generally found in hen or turkey serum and hen or turkey egg yolk.

[0068] In some embodiments, the TCRγδ-specific antibodies and antigen-binding fragments are human. In some embodiments, the human antibodies or antigen-binding fragments are generated in transgenic mice that generate chimeric antibodies in which the VDJ regions are human and the Fc region is mouse, for example Ablexis™ (alivamab) mice. The VDJ regions are sequenced to produce an expression plasmid for a recombinant human antibody with a human IgG1 Fc region. The expression plasmid is used to transfect mammalian cells, for example CHO cells, for fully human antibody or antigen-binding fragment production. In further embodiments the mammalian cells are CHO cells.

[0069] In some embodiments, for use in a method to generate a cell therapy product for administration to humans, non-human derived antibodies or antigen-binding fragments may be genetically or structurally altered to be human.

[0070] The antibodies may include monoclonal antibodies including human and humanized monoclonal antibodies, polyclonal, antigen-binding fragments, bispecific or multispecific antibodies, monomeric, dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity.

[0071] In some embodiments, the antibodies are humanized antibodies. Humanized antibodies may be chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab’, F(ab’)2, scFv, or other antigen-binding subsequences of antibodies)ATTORNEY DOCKET NO. JBI6882WOPCT1 that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin sequence. The humanized antibody may include at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0072] Humanized antibodies have antigen binding sites derived from non-human species and the variable region frameworks are derived from human immunoglobulin sequences. Human antibodies have heavy and light chain variable regions in which both the framework and the antigen binding site are derived from sequences of human origin.

[0073] The antibodies or antigen-binding fragments described herein can occur in a variety of forms but will include one or more of the antibody CDRs shown in Tables 1-5. In some embodiments, a TCRγδ-specific antibody or an antigen-binding fragment thereof are provided, comprising a heavy chain comprising a CDR1, a CDR2, and a CDR3 of any one of the antibodies described in Tables 1-5. In some embodiments a TCRγδ-specific antibody or an antigen-binding fragment thereof are provided, comprising a heavy chain comprising a CDR1, a CDR2, and a CDR3 of any one of the antibodies described in Tables 1-5 and a light chain comprising a CDR1, a CDR2, and a CDR3 of any one of the antibodies described in Tables 1-5.

[0074] In some embodiments, a TCRγδ-specific antibody, or an antigen-binding fragment thereof are provided, comprising a heavy chain comprising a heavy chain variable domain of any one of the antibodies described in Table 6. In some embodiments a TCRγδ-specific antibody or an antigen-binding fragment thereof are provided, comprising a light chain comprising a light chain variable domain of any one of the antibodies described in Table 6. In some embodiments, a TCRγδ-specific antibody or an antigen-binding fragment thereof are provided, comprising a heavy chain comprising a heavy chain variable domain of any one of the antibodies described in Table 6 and a light chain comprising a light chain variable domain of any one of the antibodies described in Table 6.ATTORNEY DOCKET NO. JBI6882WOPCT1 O QNESDI 621814203633FS T T V T REIGTG VSN HSMbDRC QTYYA QPFVTD Y VRA L MIPQPS SCNTSSVS SNTY V NGSVSSVSO QNESDI 51171329253) 2R P R P R R R R N RMbMbDY SCS S SKAT SNGSNNKSA A LLTA G AS V S V(AP E SGP E SsecnOeQNu E 0 6 2 8q SDI 4 1 1 2 243esR1LL YDNDN RSDYS Q YSNSNS SLSYSA YSYDMQDb DSS T S S TGVTGSDY STGSC C A LSN A V RDAA GLGG V GSGG VriLG D R VL TD NTV Y Q R RTV Yeht nidanmao1 2 3 4 5 6sDLVLVLVLVLVLVeidOoNbQit ESDI 3 951127233naδ3SγRV FT Y V E FFI IFIDI SG V Y D YSDFK K VAA VARMbD G C G R Y V Y M G Y GTGFA D GFCI D G D N V DIVAT A H DTD DTYE S P IG -EDIGitnOaQNyESD 4 0 6 2rI 2 8 1 2 2 3alp 2SSSSG S I GS NG meR M DSSSDS YTYNS PN SY NT Sx bCS I S INIYNE A HI II T ITYIT1 SYSY R N RIW G RIelbOaQNTESDI 1 7319152131RGN NS NTH NM M SNSNS S I S SbDFTT FTMISWISWFTYISW CFYFD G Y G Y Y Y G Y A H G A G Y A Y G Y G G G Y niamo 1H2H3H4H5H6H D V V V V V V yd9 8 1 4 2 3o7b99383449 5it B B B B3B4B n9G9G9G9 9 9D G G G AIV V V V V VATTORNEY DOCKET NO. JBI6882WOPCT12484450666278748TST T T T T SYTSTS S S SGT SIYSV Y VTY VTY VTY VTY V YYSVSSSVSSSVSSSVSSSVSSSVSQP LQTQPSQYP1474359556177738P P P P P PRNRSNR N R N R N R RSL TVS S S SNS SE SVE SVE SVE SVE SVE SA GT SA A VSQ0464258546076728DSNDNDNDNDNDN ISYSS Y GTGGSSYSTGSSYSTGSSYSTGSSYSTGSSY T GSQSS ASQS LYTG V V YGTG V V YGTG V V YGTG V V YGTG V V YGTG V A A V Y R VALA RRS7 8 901112 3 4LVLVLVLVL1VL1VL1VLV9354157536965718I I I I IT Y VLIK K K K K KIV DEDVAFVAFVAFVAFVAFVAFG Y MFGVG Y W AIA GVIA G A G A G A G A V GVIGVIGVIGVIG DDTG K D Y D R8344056526864708GSGSGSGSG G SSNS SS SSIY YSYSYS SS Y WTIN TIN TININYINYINSII LIH RIRIRTIRTIRTIRTI SYLD7334945516763797NSN N N N NN TIS SSWIS SSWIS SSWIS SIS SISSV F NTG YSW G YSWLG Y G Y G G YSW G YTMSV G Y G Y G Y G Y G Y G YFD G YFGGSG70 1 2 3 4H8H9H1H1H1H1H1H V V V V V V V V7434054 2 9 3 04 4 46444540 7B B B4 49B B B B BG9G9G9G9G9G9G9G V V V V V V V VATTORNEY DOCKET NO. JBI6882WOPCT1061228524 0 6 29 5 535454555SSV G V PD YLM Y Y D G G GLIEDYSGS EY WDGDFGPMTE PD A YSIWFA DFY Y Y G Q GED G Y DFVGSD H Y K D Q M VSDFPDEFN R951127 3 9 5 18 5 52535354555R DSSSSGSSN DNS SNS SSYSISG Y TTS FIGS FINS SGSSPI FSISYIHTSRIYYISYIAS SYSYFGISNISDIHKE84102622 8 45308 5 5 5354555NST K S S N NSYSFA RSNSFNSF SSFASFYSLGSDGAKTGI ITDFMFAIG YFM TMTMTMTMSM N GSYFGNF FA G YFAFAFR G Y G Y G A M5161718 9 0 1 2L1 1 2 2 2VLVLVLVLVLVLVLV7319 5 1 7 3 98 5152535354545SDYLR S T R R R S A G N YTYTNL TG YT GFTG YT NL TWRSESY SDFHLKFQPSQPQYA QPHLY QPLQLQLQWQPSQPSQPY62 8 4 0815152536532548545GTR L L RTS T T RRSRSL NFINRT SAS S S S SSN GTA A ASA Q ASA Q GTA A GTA A GTATVSQ51171329525 1 78 5 5 5354545GSIN S L I I QYG QVLGALS L Y S L QYS L I Y VASWSQ QS S SQTQLD YSASS SA HSY A RSSSASS SSS SY Y R V A RNSA A A G R N R V A G V A R V A RSS5161718 9 0 1 2H H H1H1H2H2H2H V V V V V V V V2891425203435603 1 1 1 17B B B1 1 19 9 9B9B9B9B9BG G G G G G G9G V V9V4V4V7V8V3V1ATTORNEY DOCKET NO. JBI6882WOPCT1 O QNE 62908104 0 6SDI 1112121t3FS T T T a REIGTG VSN VSbaDRC QTYYA QPFVTD H Y VRTK L MIPQPS SCNTSSVS SN Y V NGSVSSVSO QNE 5107 3 9 5SDI 9 101111121)at2P R PtbaR R R R R Rab Y Sa D CS SKSNNNK(K LLT SA A GTG A ASSN PVE SK GSSPVE SsecOneQNE0 6 2 8 4SDI49010 1 1 2u1 1 1 1qesLYD DRt1aRSD L Y S DbD QS DS TQY SSN SSN T GS SN YLV SSA N T GSD YSY YSTGSCaC N A V K LSRDAA GLGG V GSGG Vr LG D R VL TD NTV Y Q R RTV Yiehntiadnmo1DL2VL3 4 5 6VLVLVLVLaVseiOdoQNbiE 3 9501 7 3tSDI 9 9 1111121naδ3SFT Y V E FγtaRV FIKIFIDI SV D G Y D YSDFVAA K VARbaG C G RIY V Y M G Y GTGFA DIGFAC K H DTD DDTYGEDSNPVIGDEDVIG T-itOnaQNyE4 0 6 2rSDI298901111121alp 2S E S G G N G P S SQG PmteaRSxbaDSACSFGSSA KIYSSN SDKSY YVTYN KL SYSNPNFSN KNTKSYSK K HIS IYVSSIS IYSDIRTNS YPIN RTILISY QYW G A GIN RTILES2elObQNaTE3 9 5SDI1979010111121t1N N NS SaR M WHDMTWIW baD C Y Y Y Y Y Y Y Y Y Y K H A NSN G N niamo 1H2H3H4H5H6H D V V V V V V yd9 8 1o7b99 8442935it B3B3B4B3B4B n9G9G9 9 9 9D G G G G AIV V V V V VATTORNEY DOCKET NO. JBI6882WOPCT12383440156 2 8 41 1 151616171TSTTSTSTSTSTSS GTYSIYSVTY VTY VTY VTY VTY V YYSVSSSVSSSVSSSVSSSVSSSVSQP LQTQPSQYP137334945 1 7 31 1 1 151616171P P P P P PRNRSNR N R R R RSL TVS SNSNSNS SE SVE SVE SVE SVE SVE SA GT SA A VSQ036324844 0 6 21 1 1 151616171DNDNDNDNDNDISNSYSTGGSSYSTGSSYSTGSSYSTGSSYSY S Y T GSSTGSQSSGASQS LYTG V V YGTG V V YGTG V V YGTG V V YGTG V V YGTG V A A V Y R VALA RRS7 8 9011 2 3 4L L1 1 1 1V VLVLVLVLVLVLV92531 7 3 9 5 11 1414151516171I I I I I IT Y VLIK K K K K KVAVAVAVAVAVAV Y DEDFGF F F F F FG Y M W AVIA G I A G A G A G A G A V GVGVIGVIGVIGVIG DDTG K D Y D R82430 6 2 8 4 01 1414151516171G P G P P P P P S SSSNSN GSN GSN GSN GSNSSA G K N YISYYSIN KSY YSN KSY YSN KSY YSN KSY YSN KSY YSN KSY SYRTILS IRTILS IRTILS IRTILS IRTILS IRTILSIS IVYSWL TKHLDILDSP723 9 51313141157153169161S S S S S SNW W W W W W M GY Y Y Y Y Y D VY Y Y Y Y Y Y GSG N N N N N N NTV7 8 90111213 4H H H H H H1H1H V V V V V V V V74340546249 3 04 4 45 0 7B B B4B4B4B4B49 9 9 9G9BG G G G9G9G9G V V V V V V V VATTORNEY DOCKET NO. JBI6882WOPCT1088546076 2 8 41 5 5 575858595SSV G V PLID YLM Y Y D G G GEDYSGS EY WDGD G TPA Y F YSFYPM Y GEQDFV SS DFIWFA H Y E K D Q M V D GED G Y D G DPDFN R9775369657187 31 5 5 5 5 58595R DN SDS SA S V GSSY GSY KSSA GGA S DTKSY KSKSYISY G YVS TY G N G SFIK G Y SFIKNSSYSNNSFISIVSSIYIASSITSDSVSV FK GSPISYVSHTR D Y Y D A G A GISY NSDISY DSDIHKELS876526864 0 6 21 5 5 575858595NSSY A N NSA Y G MSD MMGAKIAMYSM M M A YNFA A YRA NTGIDTR KYSYSN N M51617 8 9 0 1 2L L1L1L1L2L2 2V V V V V VLVLV7755167637975811 5 5 5 5 5 595SYR SDLA G N T R G R R S YTYTNTT G TGT NTWRSYESSDFHLKFQPSQP LQYA QPY HL FY QLQL LQWY QPLQPSQPSQPY674506662 8 4 01 5 5 575758595GTN YSR L L R R R LTK SSTSTSRSS SNFINRT LNSPA GTA A ASA Q ASA Q GT SA A GT SA A GTSATVSQ573 9 5 1 7 3 9155556575758585N L I I L I S L LW S QYG SQ VLG QALS QYS SQ Y Q YV QAYSASASYS S S S T S LYSSH RSA RNSA ASASSASY R N R V A G V A RSA G R V V A RSS516 7 8 9 0 1 2H1H1H1H1H2H2H2H V V V V V V V V2891425203435 03 1 1 16 7B B1 1 1 19 9B9B9B9B9B BG G G G G G9G9G V V9V4V4V7V8V3V1ATTORNEY DOCKET NO. JBI6882WOPCT1 O QNE682198194 0 6 2SDI 102121222aih3FET t RIS T T T GTGSN VS SohDRYYC QT PA V F VTD H Y VRNTY VTY V C L MIPQ QPS SCNTSSVS SNGSVSSVSSSVSO QNE5SDI81197193109205211222)aiai 2P P R R R R R P R RhthtRoho Y Sh D CSC LLS SKAT SNNN NGSNS SCTA G A ASPVE SK GSPVE SVE S(seOcQNneE D48096920804102uS I 1 1 1 2 2 2 2qesaih1LL YDN RSDYSL DNDN Q YSNSNS SSYSA YSSYSSY RtoQDh DSS T S S TGVTGSDYTGS TGSD C C LSN A V RDLAA GLGG V GSGG VGG VC G D R VL TD NTV Y Q R RTV YTV Yrie nihtamo1L2 3 4 5 6 7dD VLVLVLVLVL LnV VaseiOdQoNE3898591070319i SDI 11b1 1 2 2 2 2tna ai 3SFT Y V E FIδγhtRVoI SV Y D YFSDFKIF A A KIA KIA h D D G G M V C R Y Y GTGFD V GFV GFR G C H DITY V D DDTG YG D N VADIVAVACE S P IGEDIGIG T-itOnQNaE2 8 4 0 6 2 8SDI8 8 9 0 0 1 1y 1 1 1 2 2 2 2ralpaih2Yt RSYSNIGI Io DS SGIGSSN G G mex hCSC HSSSSS TYSYPSN YSSYSY E3eOlbQNa E1 7 3 9 5 1 7T SDI81819191021212aih1N t RG S SSNSTNSNSohDF FICTFYTF SIGSFGTIY YSIGSG C H G A G Y A Y G Y G G G Y G Y niamo 1H2H3H4H5H6H7H D V V V V V V V yd9 8 1 4 2 3 7o7b99383449 5 4it B B B B3B4B4B n9G9G9G9G9 9 9D G G G AIV V V V V V VATTORNEY DOCKET NO. JBI6882WOPCT18243046425854 02 2 2 2 2 26272TSSTST T T SYSVTYTS S SGT SID YSV V YSVTV YSVTV YSVTV YSV YYVQP LQTYSGSS S S S S S S S S SQPSQYPQ M V7233935415753692 2 2 2 2 2 262P P P P PR R R R R R L RNSN N N N SVS STSNSE SVS S SE SVE SVE SVE SA GTA A VSN Q GSP6223834405652 82 2 2 2 2 26262DSNDNDNDNDN INSYSSYSSYSSYSSY S YSGAL SYTGS TGS TGS TGS TGSQS SQSSDGTG V V YGTG V V YGTG V V YGTG V V YGTG V A A A YSAKV Y R VALRRSGTGI ID80 1 2 3 4 5L9L1L1L1 1 1 1V V V VLVLVLVLV52137 3 9 5 1 72 2324242526262KIT Y VLISYVAKIA KIA KIA KIA V Y DEDFDLGFV GFV GFV GFVFG Y M W A WASYVIA A A A G A V GVIGVIGVIGVIG DDTG K D Y D RRESSDF420 6 2 8 4 0 6232324242526262I I I I IYSH D NGSGSGSGSGS SNGS S S S S TY Y Y YSYSSWLTF32925 1 7 3 9 52 2324242525262NSN N N NNISISISISST TGSSGSGSGSIGS F LGTFSFVIGSD G Y G Y G Y G Y G Y G Y GSG Y80 1 2 3 4 5H9H1H1H1H1H1H1H V V V V V V V V3405462 9 3 0 24 4 44454047 8B B B4 39B B B B BG9G9G9G9G9G9G9G V V V V V V V VATTORNEY DOCKET NO. JBI6882WOPCT1 O006 2 8 4 0 6QN66061616263636ESDI72G V PLI 3FLM Y YEY D G G GEDWDGDFTEIF YFGYPMTY GE PQDA FVY S DSIR Y W A G DRQ P H K D CTD GSED G Y D G DFDEFN RMIL MIPO9 5QN9 01171329253 E55 6 6 6 6 6 6 SDI72YSDTRYSG Y N DE )T T2S S G SN D RSSSSSSSSSSSGTSSG SSN S YSG G D FMCSIM L(ILTs8 4 0 6 2 8ecO QN950616162624636neu ESD4I72qTeSSR KSSSS N Ns 1DTFSF FSFSFSLT RLNTFFIFTFTFTFTFSFM R R D G DLG CMCSD G Y G Y GFG Y G Y G Y G Ar IL Q D Y ie6hn17 tiaL18L19VL10VL21222V V V Vd m 1VL L L n o La D V seidO7 3 9 5 1QN9 07 3 oE35 60616262636biD 7tS I 2R S R Rna3DG N T G R G SY YTT RRIY TTNTT G T T N δHLKFP LQYPY HL FY QLQL LWγG G DTD C DSFQPSQ A Q Y QPLQPSQPSQ QPY R CMIR H AVI SG T-itO6 2nQN9 0804102622 aE25 6 6 6 6 636 yrSDI72aR L L R R R Llp 2YSST T R S SN m T RSDSAT SAS S S SS eG CSSG A ASA Q ASA Q GTA A GTA A GTATVSQxEMIHSI I4eO5 1 7lQN9 0 031915213bE15 6 6 6 6 6 6aT SDI72L I I L L IS G GAS L1Q YS SS Q VSLHQS LS YQ YSSS QSYS SS Q YV STQ ASLT RGG DF TASA RSASSSY CTFY R V A RNSA A A A R N R V A G V A R V A RSSMIH G A617ni18 9 0 1 2aH H1H1H2H2H2Hmo 1H V V V V V V V D V 914125 120 134 135 160 17yd97B B B B1 o 99G9G9 9B9B9B9biB94G G G G GtV4V7V8V3V1 nG V9V ADIVATTORNEY DOCKET NO. JBI6882WOPCT1288 4 0 6 2 82829203031313S T T T TGTGYYA VSN V T D HSTST TSTQPFSV Y VRSN Y V Y V Y V QPSCNTSSVSNGSVSSVSSSVSSSVS187839995 1 72 2 2 2031313S S SNA GS S SG AVEK GVEVEVE08682 8 4 02962 292031313SSG YAVVLG V YYG Y G Y G YSD NSV V V N Y D N S Y R D N N N Y D Y D Y Q YSNSGLSSSGSSGSSG2L3L4L5 6 7 8V V VLVLVLVLV975 1 7 3 9 52829292030313G Y M Y G T G F D G F G F G FV D G YGD NP VADIVAVAVAD V RIGIGIGIGRTATYESF I EDV Y D AEYFSDFG K A VIR A AFG K A A VIG K A A VIG K A A VIA874280296292208304313YSNTIG TITITISSGSIGSTSSG G G YSNYPSNT SS SYS SI I I T I IYIYIYI773 9 5 1 7 32828292030313NS SF SNSTN N NT I FS S SF SISG YTYI I ID G Y Y YSG YSG YSG Y G Y A Y G Y G G G Y G Y G Y2H3H4H5H6H7H8H V V V V V V V891844293 7 33 3 4 354444B B B B49 9B B BG G9G9G9G9G9G V V V V V V VATTORNEY DOCKET NO. JBI6882WOPCT1420363248 4 0 23 3 3 343536346TST T T SY SV ETSTSTSTGT S SY WDYY ILDGFY V Y V V VTYD GSSVY Y SSSVSSSVSSSVSQPQ QPSQYP S SR Q M V AGLY32925331 7 3 9 13 34343535346DSVS S S SEVEVEVEAS SASNSSG V GSI IY2282430 6 2 83403 3 343535346GSSYA TV Y G Y G Y G YRSN V N V V AS GI FDSSY D GSSY D N Y D N YVGSSGSSGS IG N D YTQ Y QSSDFA G Y90111213141516L L LVL1V V VLVLVLVLV1272339354157593 3 3 3 3 3 336G F F F F G Y M W A W A Y RVIA G GVKI IA G GVG KI IA G A V GVG KI IG D D G K Y D DR SG KIRTY V RLE SDG RS FYTGTRISDYLHLA V A A V A A V A A V A A V Y D AEDFA QPS02622338 4 0 6 83 33343535336TITITITIYSD NGSG GSSSSG SSSN G SS TSYSWIYIYIYISI ILI T TA HFI TG9152137334945573 3 3 3 3 3 336NSNT SISN NNSISISI SFT GGSI SSG YSG YSG YSG YTLFDSFVSVY G Y G Y G Y G Y GGSD Y G G YSQ Y9011121314 5 6H H H H H1H1H1H V V V V V V V V054624953007294B4 4 4 4 483119B9B9B B B B BG G G9G9G9G9G9G V V V V V V V V9ATTORNEY DOCKET NO. JBI6882WOPCT1 DI844 0 6 2656666678676Q ESO6N63Y F Y P M ED VDSIYW At3FSED Y G Q G Y DFGSDFPH DEK N DcaREIR M Y R Y V K A G D V G D AGT PR G RFA A Y APR R G ALIEDtFnoDRC Q C L MIP7 3O4659655661677676QNE5SDI63TRYSGND E)t tc 2SSSGSN DcSSS Sa aR TARGTS IGS INS tntnoDYCIL YSI ISI ISITSSIYSIYFIKoC C L (LSLse DI64265865466067667c6neQ uEO46R Kq SN3SFSS S N Nestc 1D LIFSTFSFSFSLG M RatR DDSYTYF S FTGF FATG YFATG YFASG YFR G A DnoC N W G YNC C LDLG D ri718 ehniaL191021222tm 1VLVLVLVLVLVdn o La D V s5eiO41575369 5dQNE36 6 6 66676 obitSDI63S T R Rnt3DNYTNTG R TG TG S TNTaδcatR GRITDKFP LQYPY HL FY QLQL LWγnD C DSFQ A Q Y QPLQPSQPSQ QPY RoR C H AVSCIG T-i O4 0 tQN4 565268647 n E26 6 6 6 6 6 ay SDI63ralS S S S SSptc 2SRII Y matDSSSA A A A A A A G G GTVexnoC VSSE C H WSD 53 9 5 1 7 3 elO QN4 4656 6 6 6 ba E166 6 7TSDI63H S S TN RS S S YStc 1MSINI SVSVSVSIatR noDTYG GS S SV C A Q Q Y Q Y Q Y Q Y Q C H G N718 9 0 1 2niaH1H1H2H2H2Hmo 1H V V V V V V D V 425203435607y 91 1 1 1d 7B B1 1 o 99 9B9B9B9B9biBG G G G G Gtn 9D G V4V4V7V8V3V1AIVATTORNEY DOCKET NO. JBI6882WOPCT1278748096 2 83 3 3 3930404S T G TSN V T T TGYYPAFVTD HSYRNTSYTSYTQPSN S VS SNGSSY QSCT S SVSSSVSSSVS17773898591 73 3 3 3 30404GAAPEP PEPEPEPYI RYL SIRYIR G Y RYIRYIRYRL SAM KLSGM NLS IN NNVVLKML SNVML S INVML SV07672888490063 3 3 3 3 404L RYSY YSN S Y S Y S Y S Y S G V A G V G V G W GVLY G Y Y Y Y Y G Y Y G Y Y V G Y Y A A V N W V N WSW V N W V N W V N W2L3L4 5 6 7 8V VLVLVLVLVLV965 1 7 3 9 53738383939304GV Y MD D G Y TGG T F F F F D N G V A D D G V A G A G A YPYEREF DIG G KE IGVIGVIGRTSFRDFG K G K G K A V Y D A YS FA V A A A A V A A V A A V A864370386382398394304SISIY N YI NYNYNYNSYIS RT IGIN RTIW GGS IGIIMNRTIIRTIIRTIVSGGN GGGGGG WSWPNT I I IWSSY WTSY WSSWSSWSS7637975 1 7 33 3 383939304MD W WHYIW W W Y Y Y YY YNY Y Y NSNS SGY Y YSS NTNS SNS SNS S2H3H4H5H6H7H8H V V V V V V V891 4 2 3 7 338344935 4 4B9B B B4B4B4B G9G9G9G9G9G9G V V V V V V VATTORNEY DOCKET NO. JBI6882WOPCT141026422 8 4 0 44 43434445486TSTSTST TST TSSYT GYSISV EDL D Y WFY Y Y Y Y QPY GSD GSSVSSSVSSSVSSSVS SQ QPQYP SR Q M AGL31915421 7 3 9 34 43434444486EYPEPEPEPGAVQGPIIRSD NYIR NYIR NYIR NYRYLYRSSML SVML SVML SVML S IVL SLS IAL TLS INALL SVSFN WSS IY21814 0 6422 8 24 43434444486Y S Y S Y S Y S LAYG V G V G V G V YG Y Y G Y Y G Y Y G Y YSYLY D W A A Y W V N W V N W V N WSW YKA V N A ARSWGI ID YTSM90111213 4 5 6L L1 1 1 1V VLVLVLVLVLVLV11713 9 5 1 7 14 4242434444486G F F F F G M W A RVIA G A G A G A Y A WSGVIGVIV GVIG D D G K Y DRSDG YG K G K G K G K RTTD Y R RLERSS FY HLA V A A V A A V A A V A A V Y D AEDFA DLQPS016 2 8 4 0 6 0414242434444486YINYINYINYINSII LITFIARTGIRTIRTIRTISIGGIGGIGGIGSY VSLH T SALD R N G A NGIGYTIR WSSWSSWSSWSSWSSY W WIWTNLLSS905 1 7 3 9 5 9414242434344476W W W W MY Y Y Y D V WAYLY Y YGGYN N NY N YSNTTV YSYS S S S S S S SNSGGSNSSW9011H12 3 4 5 6H H1H1H1H1H1H V V V V V V V V054 2 9 3 0 294644454047 8 1B B B4 3 19B B B B BG9G9G9G9G9G9G9G V V V V V V V V9ATTORNEY DOCKET NO. JBI6882WOPCT1 DI096692608704 0Q 71727ESO NY F P M ESYD VDSIW AED Y G Q G Y DFGSDFPH K DEFN DR M R Y K R G R ATA A APR)A G D V G DGR G ALEDFL V(n98591i07 3 9 a6 6 7071717moIHI I IdG I I D EeSRVS YS YSS VS ASYSG SSNS SSN H A DlbWSSITWSS IVSY VTFY WGSTSWSS IV GFY WSS I LN Y WSF SaKiravni8a8490060218 h6 6 7 7 717cthMgSYNA A A R NiMlRFN YSY A Y Y A GdSNKSMSSMSSMNSMNSMna)H718L19 0 1 2V( sL1L2L2L2LeiV V V V V VniadoL boiV m7 dtn83999501 7 eania6 6 6 71717lbδ maγ oirR DS R CN TYNLG R R G SaT YGFYNLv -i DIKFPQYPHLPQLPQLPQWPni tQ Q A Q Y QLQSQSQ Yahn EO cay SN r6 2 8 4 0 6yv7 7 7aal8696960 1 1e phfmeA A A A A ToxAYA G G GsefIQ YIQ YIA RYIAYA V YQLec oLLLTSLLLTSLLRSLR LSISLR LSISLLNSneuqes581 7 3 9 569696070717dicaVLALALALAoLA niHNY Y YYSYYSYYT LY Y Y m HSR W N WSSWSSWSSWSSA W6V el718 9 0 1 2baniaH1H1H2H2H2HTmV V V V V VoD 42520343560y1 1 17 dB B1 1 1 o9 9B9B9B9B9biG G G G G GtV4V4V7V8V3V1 nADIATTORNEY DOCKET NO. JBI6882WOPCT125456 84 45454WSK QQH ADILKQ E Q QPYL EYLQ QQLTTYL GRWSIYGWSINFGDW TA SLI STVTLS S TLDGYL LV NASDS TYASGDSKSISTFY N ADN NLYTNLGEVTGGSV GGLSSFVSG KRKIV DK TLG VS LTQSG D NSK D KSVQSSDPGSASVS GS T SSGTLR V QRGS KTGFCSG G CRGTSFKIS F S F TG GTNG GRTSATILR QC SA RPTDPGSII F TG VC NG SSG VPEYFASEI R IGFT TISSPVINTG GFRT IS SVGLR D GTY APQKTQPVPTQTY PRPG SPSG GRNSTVIMSP LL CL SSS S SG APA GGS SSS AFSG VTLYSQLP YILTG YV YICS EY YSGYIQ C QSM VS I SPSGSVALYMC QP LCPYAYQ G DS LY QKPDP LK YT P EQTRPYTLAA QT PDM KVI Q AEMSV K Q VEDLAAEE LV V Y RIEG APFAGD QPHE EK ASSGPDE1L2L3 4V VLVLV15355 74 45454ATVW C T SGV SG SICER YSLSIYLASE DRH GVT ISTR AM VITWTG ALGTA CLFV GSGSIY Q V G C W E DIC TG CGD VCSR K RALTQLR KTFAWTL L SYTGMY QL LGSY YSVSGPG G KDEWLSGPR GTD VSDLKTV GSLKMTVTG AGQ V A Y G A Q KEMTEG V AR ATWITEG A VAVPRSER RTML DF GPRVSA R GSP P SD D QK F SP PD QS TK VAVFSI SK V DLYLW ASY KRATI LAN KRIKLA A G Q NDG I MRIVLW N Y N YVLSWP TVPFVLW SP TGGGMYS QLTG MYIM Y Q DGPN N YSFSGP SNVSWIGTSYSEASYSSLSVG D I G Y YSLTTG WN TLG G W YSY NLAFDSENSYLVSEY YTNKLDS SEYTIKLAV GFSISN GV SFSS SGSSQLSSGI SF EQ NSGS SGLQTSK A D RSLT SIN V KVQIVFVEGSN ASW D CVQ TVFSEGS SD A RTV N AVTVS TH YSLQIGYQ AIN Y R KGSEVTVS S LK Q V GYQ GIN G R K V1H2H3H4H V V V V97891849 3 34B B B49 9 9BG G G9G V V V VATTORNEY DOCKET NO. JBI6882WOPCT10626466684 4 4 464P E QQLQQLQQLQQKAQGQGQGQLQLQ A Y WSIYSIY WSIYGSIYGS TWT S TWTWTRI LT VS SLSVLSLY VSVSAL AS NTYAN NTYAYAN NTNTYAYSGYGY N Y NYT LG GS LGS LGGGGGSGSR DV KGK KLKLLSGS TV VSVTVSV T VSV T VSV TDS DGSKT SG SSVDFKSG SSLDSGLDSGLFK S SFK S SFKQ GSGTG RT TRT TG RT TRTCFGTNSG GGTNSGTNGGTNGTIRGR DFCG VV PVSIGGFCSIV GGFCSG SIVCSG V GGF SI GFT IG VTI SVTSVTI SVTGSV S HS PR VIS PR VS PVIS PVQGPN QLRGGN SPS TQ S GN SSTQ RSSGNPS TQ RSSGNS TSA NSNSVTPYSVT SVTPSVTVNSK DGEYS GEYS GEYS GEYSV GRSVI S SYI S SYVI S SYI SA YSNSMCVYSMCSMCVSMCP IDVCALQLYPYALY YALY YALY Y QKPDPKPDPKPDPKPDTVYTAA QTAAQTAAQTAALPA D ALKEDLKEDLKEDLKEESSQ GEADSGQPHE EGAYS PHEAASGQPV G DHEASQPHEA5L6L7L8L9V V V VLV9516365674 4 4 464K S I T S I S I S IC EVS LVA SSVTW D AS V GISG RTVCG VCS TG C WTDA V GISCT TGGC W DA VIST WTG DAV GTTL SYV G V S G VCSCG VCSK Q D GQFDVLGMYTTL LGSY YSTVL LGSY YSTVL LGSY YSAS PKSRLTSLK GTV VAVSMLKMTVTSLKMTVTSLKMTVVTA A Q QLGTEAPRS TDTTEG A VATVTEG A VATVTEG A VATVGP RASRSQ GSPQKA G QSP PRSDMTSP PRSDMTSPRSDMTR VNTLEWKRI LS AG K Q RKLA A G K Q RKLA A GPK Q RKLA A GK WIVP TVISTQVISTQE IVISQV HY MDLWNV WI L PGL PGP TGA YGSYFGSW YSS A G WSNVSWGYSG N VAP IG WSNVSWLIG WSNVSWIP TDGY N TL FAPG W Y NSLAPG W YSLAPY G WSLAQTN SIDSYIKGLGSY YTFV FI IKASY N YTFY NFIKASYT KAL TSWT EQ RQ NSS SLKEQNGLSGEQNGLSGEYQ NIGLSG G DALIS SQ VL SI SLKL SI SLKL SI SLKQ G MRCQ GYIN G V QS SY Q V QS SY Q V QS SY Q VVTY V RIV GIN G V GIN G GIN G QSTW M Y QGSGKSG Q G R K V Q G R K VVEG R K V5H6H7H8H9H V V V V V293 7 3 035B44444549BG9BG9BG9BG9G V V V V VATTORNEY DOCKET NO. JBI6882WOPCT10727476784 4 4 474QQQLQQGQLQQGQLK E PDGQPKEYSYSYSQEQPW I I IYLQLS TWTWTWRYLSVLYS SVLS SVLSALSITWSNATY NATY NATYAISLTTL LY N Y N Y NS FYTGGGGGGADRFGS SVL S TSIEKLGDSVKGKLVSGTV DSVTVSVSGTTQSKIGGSSTSL SG VDSGL SFGK SEQSGTSFK STSFK ASV ASKGRTTNCSGGRTGRT RG CS KTR GIEGTNSGTNGS FGCTSF LSVG CG VG CSG VG LR D QFRRITGF SIGF SIGF TI A PGTSP TGSSPVTI SVTI SVR IFQ R VS PR VS PR V DGT TVRV Y DG QSGN SPS TQ S GN SPS TQ S GN SPS TSGPAPGSFS RPS V QL TSVTGS EYSVTYSVTL SS S ST YPYS GEYS GEY YSSA G ASSYVI S SSMCVI S S I SLTG YLASIYSMCVSMC GYIQFSV YLALPQKTPYALY YALY YPQ DPKPDPKPDSLCPIQ QLYSLLQCLAAKAQ ETAAQTAATR YQTNYSGPDLKEEASGPDLKEPEVPGPDMSV V QAMPV AYTQ H A Q HEAIDP FDIER Q H AGGAF0111213 4L L L1 1V V VLVLV9617375 74 4 47474S I I IV GISSGISSG ST TGVTGVI TGASW EDRC T S H GFWEDCFC WT GDALVC TC W YS T GDALVC TW YSC ST GDALVCYSC SSLGSIY QTT V GCLK T ATIY ALSGSYS LGSYL S LKFAWLKT ALKMTGTVV SAT LKMTGTVVATSG VLKMY T GTVVATR VLSGPR GTD VTG DL PLPRTSDEVS AP PRS TV DTT EV SAPRS TDMT EV SAPRS TG A KEMTDMTGQ Q KVPK QPRVSA Q R GT RILD RKLA A GPK Q RKLA A GPK Q RKLA A G K V DLSYP SK WPMVILSP TQ GVILSP TQ GVILSQ PTGVLW A YSNN Y N YVG YITG WP SNVSWIG WPSNVSWIG WSNVSWIG MYIM YLV DTGTMGW YSSY N TLAKFG W Y S Y NSTLAPKFG W Y S Y NSLAG KFG D YQSYSLTPYTG V HTSG DLVQ YIAEYIAEYTIAENSLVSNVLNSGLSSGV NSGLSSGQ NSGLSGV SFSS SGSS EKTTWV L QQIVS S LK Q VLQIS S LK Q VLQISSS LK Q VLT SIN VV LT LINEGYGIN G V GYR K V Q GIN G V GYR K V Q GIN G Q R K VVFEG SSSK D A RTV N AVTVSQF LGAK LST011 2 3 4H1H1H1H1H V V V V V462 9 3 044B45404749BG9BG9BG9BG9G V V V V VATTORNEY DOCKET NO. JBI6882WOPCT1082 4 6 8427272727LQ AQFSY S YS LQQRLSQ RLSV QRLSV Q RTYLVSVTNTV N V VSNTV NW GTW V A KLW KLTW K VKT WSKI IA M ATN A N A N G NT SNDYLSA N D D G QMSDQ M NDG M Q A RD VASLYRGYRVTS SISGF RSGY FIWR IW KSIWSS TGTIG TFTYSFTFYFTFVF FRNS LTFRSD IK KFRDFTR DTG TFG GFGG YFG G MFKSS SGSK G GSK D KGGG ASGSVSTSG AVCFGASLAVSM VASY A D F C DEC D G A Y A C DSRGC ATDVSLA WAV YS SAPSYIPV R Y DLY R YE LY R YLR YV V YL FIRL IRL YIG L TSR GGS SYAC S TARC SYRVSGQSPG MG DSY GSY GSS CGGGRSPSYGPSSYGPSSYGP SPNSKSV VYGASQSKSIQSGSSN DVIS A EIHA VIYA VIAVGYSYS L TGSDL S TDL S T L SPIQ G VEG G VEG G VDEG G VPLCQLY G W A R G W D R G W A G W YST KEELL S ELL S ELR S ELL PDVGS EV GS EGL ELGV A AS T E LK NLK N V KSI LK Q MLQGPDEV GEPQGAQLVE PMEGAQL SVE PM QGAQLVE PA516 7 8 9L1VL1VL1VL1VLV9712325 74 7 72727SV GT IT R I AVL F A T AL T TRYITLGFAY TG I RI LFALC W DT D VC Y V R CLRFDLP CTLLTF TF LL L SLS P T SI K DPCT LTF TR YCLRSGLMYTLAGRT P TA IK TP ET PYSLPATKTV GTQ VAQ AEGGSGVV G YRKGSSNVTRKGS T TN A Q GS A RTP P SD GRE PK A W G KSQGH D S Q GGCVPGSY K DGPGS LRK GQG K G QE PG K QK QLAYPQFYSQSCVQS QCPV RISTDS RA QFYSQFYSQLYPVFLSY D YSRYA Y RLSYGPN NSYYTLLW TA PIV ALYSSWP TS S YALWP TLW TAG WSYNLAEYTK SGLGT FD KISP VVFLGVKSP ALV GAFKGLQNLSSS PSYSA REEPVSQ HSD EIDSYSD EIP YES SLGSGF SQSDTSSSELKT TNQSL PV QTRQNL P LQSTSQIVSTTQ DFIN WLVRVISA GRSG MITQKGQYTGIGSALS T L ITQKQDSAI P IGSALS T LVG VSQ G RKS ESS EQSI Q S GDQSASIQIEQS51617 8 9H H1H1H1H V V V V V289 4 5 031 2 2 3B19B1B1B1B G9G9G9G9G V V9V4V4V7ATTORNEY DOCKET NO. JBI6882WOPCT1 DI032 4Q 73737ESO2N84SQYRVV QT RLVSS VRVLSSIV T V WSIV NTNSW NQLW K V WSDMLKLTA ALY KVTM KTY TNTA V GSGT FG M M NLTQ NDQ A D GGY RQ A DTMRD GδγGTGWSPSSG Y R V W NS SG I Q A KS WDFTG NITIR DSD CDSGFT TGF FYFR DFSF TFR W YLSLRFT A -itDSLG LSGGTSGPGGE FNEA K GSKGKDRnS FR AVSA AV FP SL LaQS DVASGVT STE yrS PQ CDSD ASCDDSSSIH CSW Y KalR V CGKL LYTNp S SA R YFR RFID RL SK R mISACLS IA Y CLSY ATL EAeA RYY GNY G D CTED CxP YYeE SV GSAATY VGN G YT NSYfGLTTKS PKSYL PFI To)P YD V SIATV SIAK HACTVILE LSSDLSS TVLATDL PLAGRG VEA G G VDEVLV( LSQLG WRG W APW GSS E EPni LPPSLLSS ERL SLDah SQNEMVG NE LGS EK A M Nc Q GPQLK MVLK NLKLQGPH QGPMTGT tVPPMS hTgM K VQYSVEALF SVEAQLQ QTL SVil CILd LEY n021 2a)niL2L2Ca1V VLVH( sehiCCLnidaohb DI921333 c itQ vn EO17 7 7ya SN84LTFFTA I L F I L F IaY TGeh ADLL T TAL T TATPGGLCL F LRL F LRI LFC L TT foTCELSRSR D P CGLP T S SRLPD PAT S TILKFEWPecSLG KGTAGRTGRT P TY nRGSY A QSGR GPGS FA QSGVAGR GPGYRKS SNeLuS PAGH QSQEKEKSQ DG RS L qG QFC GGSQ GGSQ GPG Qe GPRRYPQFCPQF CFVKS QsK VD YSQRY YSQR SQF CdPIVLSY DLSY D Y A Q R Yic VLW NG AFLW TA PIV AFLW TA PIV ASLYS YFWP T aoGMTAD KIEGLGTD KILGFK E GREPVPSYSAE P YTDISP AV GAGTFKniG Y S RPVS TA REEPVS LYSI SQDEmEARSELKTQ TSSSELKTQSTSSSELKQTSSLEPV AV GFAGRSGLVVSARSGLVVSART L IN S GQVS QLKT 7 LQTFYITG GIEQSG YITG GIEQSG YITG GIDQS TVSSG QelC bV GaHE ST021 2 nia1H2H2HhC V V V C H 435 0y 916B17B1d 7Bo 99 9biBG G9Gtn 9D G V8V3V1AIVATTORNEY DOCKET NO. JBI6882WOPCT1 484IFSVVQEKSQ EPPS Q HSLCPA A QPYE FN IGTVA N YLA D V WR F SESVQCVV KAISTK HLTP LA A A YRK WKYLIQES TN F A D V KEV YSAD VVV K DVT TK H KKTAASGR EKSKIW SQSGQEY PASD V DGR LV K AQGFYTFLRGS KTA KSTINTCSS FL R GERLTPNFLSLTD QPP GY LEI L S TC YC ARIGFT FNSSR VTESGDTY APN LLQVMSDRG NPRPSL SYCECA KSFSLSS SC VTSGYTYIGDSSQKSLA G R G YVD NGK ETVTYQSAKSFSVL TPGIQ SP LCTDKDEQV ES SSQLR YGSQ ETVADE LGTPSY VKL TPES QSQ M VSVPN V QA Q S SRPFGHTIEGP FDEDEQLG 2 CL384RS VIY G TEE G SL S DF V KAWDC T S NSSTYLG GSVSNPPD V KFV ASNSS A NT P LN GPSERH GT LNSRAGP TV VSYYFVPGSCSLSIY QSWS S PQTSW LGTGKS S PC RSY R V V G GPQLLKTV GKYKPIW Y K QPSV YK KTQSLRGFRATWST LG HKDWSVLH NPC MNFTSCEVTK WSLS PGDVPVSNVESA YSERDP TG A VP SVTLTK N KRP LYRK G A KEDALPE SV N S NHD V YYEQCALFL E TNSQ GQVA M GP P Q CFSDI SPFPFQLCI TK EQ K GLN KT PRIM G R V Y VYKP PET D CKPDE EG KSED Y VSR RNA VPV K DLTHSYF F LY VSY VIDA YTNVW A Y N YPKPQYQITSDAPQSP HP LKQ Q GLHLG N Y M Y GV FT TSS LSYS PSL VG KFTKFKVTGLPELSKWSFVTDIN TKTNKSS LG MIQD K YAG D Y YSLTTTLSC HGVLSSS IISN DTLHSV V D K A QKGSC VSKSVEMELESNSY V AGLGSPV NH I E WFHES SSLSGSASSPSKV A D AGRSN AS LGVASSTPK V D G V HLVPAE EFSMVL FSN VSA TLVGC V T P RV GVQTF ISK DVT TATTAT LATV V KLL TVEVLVL SAAP I SDS SVE S SA R V N AVTG V W D CP D C GGGSV 2 C H 893B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 684Q T T QQV K V YLGS VPQ WSSIPS CSVTA LLASDYSKPASR NAK YTQHNGWSN A K GGLSVVW VTTQ DKNS LVES G KTS TAPTG FTRGGP LGY SLC NGFD Y SSII FTG VSSVIL SISSPA N C A Q RTV Y GP KTLSTKCSSG G A GSAFA NESKN TPVYIC NSA S A QVA MCQKSTP LYL PKQKPYE TET DESTTV L AAS ETV KEDPVSAGP E PGGQ H AFLAEH 3 CL584PA PD V KL S DF K SG SV GEE G SL SP TVC R YVP SRNS TYPYLV GVV NPT I TRMC W DACTG GSSVSTPSNPD SATV V KT PVNYYP IW Y V VFPGST K Q GPT E ITQLS L L SY G QTN SW LS P PR Y K CP SIRSVFW Y V Q GCMNF SCPKTQL SGMTY GKSYHPMN TKPKTLTK N KEVK WS LK V VSS VT LNC LF SCEVHD V YY RP LYRKTGA WI PG VT TK N KRP LTK EQEQCNSQES A RS TDAVP SNHD V YY CKP PEK GTLN KT P PD QK FL E SCTK EQEQTDC K DEG KSED Y KRLATP P QL IKP PEK GLSS PKPEHRPNLA VPV HVIS APFKQ QTNLWP TNF FVPFV Y VYDK DEG K V ATCP ER NLA QELSKW F VTDSIN GLH GN N K NKSS L PYT FSSPD G KPQSP HPKFTKFLSKWSIN KV V D K QT TSYAG WNLG KVTGLPE FVTDT TKSV A NH KMELESYTKDTLHSV V D K QKMKPVD G V HL EVIPEEWE FHEY F MQLSNLSSC VSSGI SF EAG G SKSV AHEIKPV NL PEEVGKLCTVETARVSVQITLEVEVLPGVS L SAAPP IGSVS TH YSL S PG V H V ARGYN YSAT VD GC V T PSDDSCSQ AIR KGEVTAT LATV V KLL TVEVLVLAPP3C H 183B9G VATTORNEY DOCKET NO. JBI6882WOPCT1880494HQ APQQYL FE P E T K L G AHGT TKALVS VPWSV K V QSITSPVPQ Q APSSSCYGTA A DVLYSAS SYWRITKPA KNAA DSTKA R ALYSQ WYPKH A GAG N QSYT LGGSGWVL A KSR DVGT TVKSVWLV VDSVSGTTQS SATSLVEPDSSKTGPGFKTA G G GTQSG GYTRC NGP LCF FSY SISGLTRG DTVGFYIR DFVSIISGS FDSSSV PI LG V CQPV VILATQSH N V LGRPSN SSTC A S VLY KSGPRGTCLA NSN AGSVK ETYTA NET VNV YSK D N ISSKNS PV GRSASAPMC N Q A L Y A KV APYIN QLQY QSTDVCLYEETKPDLPET KEQTVYSLAEASKSGEETPDSES TVLPP ETVS EA DSQA PGSSGE PDFL4C5LCL789484SV GISI L T KIST TGTSC HGF LP LS T DTKTNSSAEKC WC EV V AT GDAC AGLVSEVFV D K QKEY MELHS LG RTL LVSGSYSSAGS SSV A KSV NHLKMYV A TLIPE WFM V Q G D LPKPV H V AEREFVSVSK AG QFDSTTVTEG VTVG ATD G G V CV TAVATG GV V KLT E LPL SAG CS PA KRVVAPP IDDSSFK AQQLSP PRSDMT S SVK QKA GTSNST LSNEPVEGSKL S DV GGPD VP RASRSVNTSYPYLNPSR VN LV RI LLG W S APTQK WVGS SLP SNSS VSSPATV R V V VFPGLK WT EY Y KPC RSY Y K Q GPQ T QSVEHIGM Y SWI P T LHPP IWTSCPEKTWLSA YSVG W YSY NLAFAV LPGESNCML NFN KR VLKRKGYNP TYTIKAPE SV NT TK YYE PCYSQSGTN SIQLNSGLIS SLGFPK VSFQ CYL IHD V Q K Q GTLN KTQ YV FISTYTKK EPEEG KSNED V HL TW DQS SQ V GPD VTDPD R NA VPTN Q Y GVYA KLG MRTQ GIN G G K R K V K VPFQTCSPP EHPK WKSQ Q N GLKHLV QSTW M4C5C H H44249B39BG9G V VATTORNEY DOCKET NO. JBI6882WOPCT1 294T FV QQQ QLLG E HCSYGTA S KTI VS VVY WT P PQS SLASSCR VSAHY DSYSNATKASK Y NPQ K RW GG GWHSQ GSKLA KEVP SVTVT DSG VTWLS SFKV QESTA RTGPLGYSTNGPTCSGYLSS SVGF F LAITGDSYAI SYS PVI SR VSL SAKSQNTC ANCNEGSSVST PPSVTLYSQ AGS EYTKCYISSA NEKN TKS V VP TMC NS PT KSALY A Q AT EY KVTVPQKPDQLSP TKETSTLA KAEEETEVG D STT VGEASGP STA H Q HEAPP EVSG 6 CL194SL S V K DII T V E FSAGSSV D KSA QTKN SAEVW D A AGLG SSV V DVTATTL PV KPV V N T D G V HHLKTSEIMEY HTEW LFM CG VCSTL SYSASSKSV VA TPKPVV G A G V V GC VVP E EF VLGMYT T LAVTD G G VLTGSTSVK LNST L T ETE VVLA VP RVS SSLSP AIG CLKTV V G T G VATM GSGSV V VK L CLTGQS SNP EPGSAPDDSSF EAPRS TTNSTE VEGK WWS SLIS VSSTYPATD V KLL KPR V H CP S V SNT PDLV KSD N GPPQ RKG L A QS SN KWSLSSPPAPPTDPA V G NP IYR SYYV GSKIS ATGSV YK C R M W Y V VFPQL V WPV W SP T LHP SIF LP SVC L N TK Q GPTQSLLGSNS IAV G NPMAPEDFPSNT T F SCPEKTWS PW YS AF LPESVC LDVFQYLC HD K N KR VVI TKV YYP LK C YRSK QGSY N YTLIKAPL GFPSNT TFQ CIHTDESRPDYAG KAKVP TKPEF QD TCSKPQEQ PD EPE EK GTLN KTQNG R G KSNED YQSV HLI SSSSLK V YLV VSYQPDYTKKDPG G KAPQ CKC LCTHPNVPTN QIFT SPYTYSG KFHLA G NVKVPA G VLSPELF SVKTWKSQ Q N GLKHLV QGSR GKS IGTS LCTHGLKPFL6C H 354B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 494QQFLG E QLYGTAHSTI V K V V WS TSVLP PQ S ASSCSYAA DYNTKPASY N Q K R GGGSG HL W ASVKVVK DSSGTTW Q SSLV TFERKTAPGTNSGGPTLC GY SSIVGT GF FDLISY SSPV VI SSQ RSLC A GNTSV A PSVTLYSSGEYTKCSY SA NETVI SKNSMC NS PQ A ALY A PKQPY DQKVLSTTAEPKLEKAY GE ETES PDHESTSTV APP ETVSG 7 CL394K DAIQTKNSSAS EV GISI T GTL T S C HGKPFLS T DITKN SNH KT EYLHTW DAAGVLSE FV K QKTSEYHVL EEVIM TPEAEWRE FFM C TGVSVS L LVCS GSYSS LAGS SSV V D A KSV NHEM YV A TLIMLPEEWE FFLPKPG V H V ARVSVLPL SAG CLKTVT TAVTD G VV TLPSAGGVSPP ID S TG VAV GGV VL CT E LPP IDD ALDS FKES A RTM GS SVKLVVVSALDSV V KTSPDV GP P SDTTNSTEEG V KTSPDYV NSYYLNPSK QKA GS SNPPD VNSYYLWRVNY VFVFTSK QPGPG KPQLTQSV RI LAQ LLK W L SG W SSP TGS S S PATV VFV NV W S VTYKPC RSY R V I W YTK QPGPKPTK N C KEVTWS PYSSI PVLH NPPNSCEVTV YRLKRK G W NLA ALPGS CMLFN KRLKEPQYE PCYSQ SYT KFPE SVT TK YYE PCYD EE EK QTN KT EYI LA G GLH RSN D YQ NSGS SGFPVFQN LCIHTD V Q KE EK QTN G GLNS PNK KLA VEQPV HLIS LKSY VYKP P ENKSEQTLN Q H VSGYQ VPD ATD KD RLA VPQ GIN G G K R K V K VF T S P EHPQ Q VTWKSN G KLP Q C PK WKSN G 7 C H 744B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 698494QQLFLG E QQFLG QTAHQL TA YGV KTYGV K WSISTS VPVSQW ITS VPVLPSASSCS SLPSASSY NAA TKD AYV A S YA KD A Y NPK R NT PK GGQ SGWHY N S GGQ G W GLA K GS LA VKDSV S GT VTW VKDSV TVTSSLK V QESG SSLK V TF TAP T FA G R TNGGPTLGRTTNGGPCSG SY SSGYIVGT GF FDLCV YSI GF FDISSPVSVI SS TG ISVSIQ RSLC AS PV Q RSLC GNPS TSV A YSGNS TSV SVTL P VTLGS EYTKCSYTYISA N NET GS EYSA VSKPVI SK SMC NSAMC N ALY A QSPYQKV ALY A YQQKTPDLST PKL AEPKQPDLKAE ETETLAAEEEASGPD STSTVT VK GD SSQ HEAPP EVSGSQPHEAPP8C9LCL597494AS I IEV GISTGTL T C HGKPF S T DITKN SAS VGISGTHTW DASAGVLSELFV K QKTSYE TMELHTW DASAM C TGLVCYSLGS SSV VSD V AHEI E WFM CT G VCSVS LGSYSV A ATPK N KPV HL P E EFLSVLGSY YSVCSSLKMTVT T LVD G VVVTAP RSV GSCSLKMTVTFTG VATV G A GTG V VL CT E L LAPPAID S TG VAVV KES APRDM GS SVKLVVVSKLDSS FV KEAPRTMN GPPQSK ATTNSTNEEG VNT PDLN GP SPQSD ATGSKRGQLI LAQSWSL SPAPD V VSYYV GSKR KLAG QQSVWLLSSG WPS P TGKS S S P P TR Y R V VFGPNV W S VPQLSVISTG TYK CSIW YTK QPKTQLLWS PNV WW YSSI PVLH NPPMNSC KEVTWSGPW YSSIRSK G Y NLAFALPGSVC LFNY RP LKRSK G Y NLAFKQTSEYTIKAPEPSNT TK YEQCY KQTSEYTIKAD YQ NGLSGF FQ CIHTD VEQ K GTLN N D YQ NGLSGV HL SI SS LK VSYLVYKKP PEEG KSEV HL SI SLKTLN Q VSQ V GYN GPD ATD KD R NLA VPTN QS SY Q V HIG KQEHPQ Q K WSN GLKHLVEG GIN G KLQ G R K V K VPF TCSPPKR K V 8 C9C H H 34045B49BG9G V VATTORNEY DOCKET NO. JBI6882WOPCT1 005E FHQQTQLLG E HV YGTA S KTI VS VVQC WS S TLP PQ ASSCYVSASY DSYR NATKASHY NPSGGQ K RK GSGWHSKLA KW VSV TVTWQDESGPS SLTT FRKV Q T AEGPLGSTNGPTLLCSGYSYS IVGT GF FSDLSYSI SAS PVI SR VSL SAA Q GNTC AYKSNC PSSSV VTLYSCNEST GPS EYTK YISSA NEKN TQ AVVSMC L NS PY A Q AKA KYQKVSP TT KPQPDT EALSTEPKTVTLKAE ETT EVETSASGPDESSTETV G Q H APPVSG 01CL994L TC HGK FIS LP LS T DTKTNGI L T K S SAEVISTGTC HG PFLS TGLV GSE FV S V VSD K QKY MELHTC W DASGVLSE FV K V AHEI E WFMT G VCASLGSV V D V AAASTT SLPK V KPG V NL P E EF VL L SYSASV H V ARVS SSGT SPKSPN KMY VV AT LVK G V V HG ATD GC VGSGV VLT ETLPL SAVVAPP IG CLGT TG ATD GC VDDSSFTEVATVG GV VLT EVTSSN VKST LE VEGSKLTSPDV K GS APPRSDTT S SN VKST LE VEG NPD VNLNPQKA GTNPKSWSSLSSSPA PPTV VSYYV GSKRLAQSWSR Y R V VFPQL VISTGKS SLSSPA PD PTV YPVTYK L H CP SPIW YTK Q S CPGPEKTQSTWLLWSGP S PNVSS V YK C RSS WI P T LHPP IWAVLP PG NF ESPSVCMNQNTLFN K HTKR VYYP LK V QEQCTYRSK N KQ GW Y TSY NLA AV G N Q YTIKF LPL APF ESVCMNPSNTLFHTK VVSF LCI TDPYK E EK GLN D YV NGSG VFQLCI TDED VYKP P EG KSEV HL SI SS LKSY VYKKP PG K ATD KDER NLA VPTN QSYQ VPD ATD KDK VPFQTCSPPHPK WKSQ Q N GLKHLVEG GIN G G K R K V K VPFQTCSPP EH 01C H 464B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 205QQF LLG E Q YGTAHS KTI VS VV WS T P PQ VLYSASAASCSK DYNTY NPASQ K R GGWHGSGVKLASK DSVS GTVW S VTV Q TSFKAEGRTTN GPTCSG GP LSIVG YFSLTGFDY ISSPVSI SQ R VSL SC A GNTA PSSSV VTLYSGTKCSEY YISSA NEKN TVSMC NS PA ALY A Q PVQKTPY DQK LSTLAEPKAKAESGPDETESTSTVTQ HEAPP EVSG 11CL105DITKNASG SITL T K FI KNAQKTSSHEYEVI TGSC HGLP LS V T DT TSSEMELHTC W DAC AGVSE FD K QKY MELHLIVPEEWE FFMTAP RVSV T GSL LVYSLGSV V S GSYSAST SPKSPV AHEI E WFM V NL P E EF VKMVVTAT LVK G V H V ARVS SL L SAIG CLGTV G ATD GC VETLPL SAIG CVSAPPDKLDSSSFTV KEVAS APRTDM GSGSV V VK LL TV VVSAPPDKLDSSSFV KVNT PDLN GPQSATTNSTEEG VT PDLN GVRSY V VYFVPSKR KLGSWSNSPPD VNSYYVPSYPGL VITK Q GPQS LW S APTQKVGS SLVS PATV R KPV VFPGLC R Y Y K Q GPQSSCPKTQL GSN KEVTWS PW YSS WISPATYH VLP SIWTCPKTQLG NPMNSKEVTWSNY RLKRK G Y NLAF LP SVC LFNY RLKRKYE PCYSQ SYTIKAPE SNT TK YE PCYSQQ K QTN KT ENGLGFPFQ C HD V Q K QTN KTEG GLSN D YVL SS SLVL I TK E EG GLSN D YENK VEPV H QIS SK QSY VYKP P ENKEV HRP LA Q QTLN V V GYPD ATD KD RLA VPTN K WKSN G KHLQ GIN G G K R K V K VPFQTCSPP EHPK WKSQ Q N GLKHL11C H 244B9G VATTORNEY DOCKET NO. JBI6882WOPCT1406505QQQLFLG E H K ESPS Q HYGTA S V KTQ QPEPFN GTIVV YL ISVWS TSVLP PQR FEYSASAASCW SA SIVS QL CA K DYS LYTL PA A N YNT PAS TA D VY N Q K RS FVKGGWHADV HGSGVKLASKT TKKDSVV VWSGR S KSGT IW QESTSL TFV QQSGS EY V DGRKTAEPARG V K K A A KTNGGPTCSGLCSSF TGE SLSIVG YFSLLTRRD QP TTGFDISYSSPV VIQ RSLSSARPIGF YFLTC A DGT TNSYSP NLGNPS TSSV A G ALSVTLYSPSRSPSLYCEGS EYTKCYELS S SC VTSG ISSA N KN T LA G YVD RVS S P TGSKN M C N AYQAALY A Q GSFPKV PILQSCTDKQKTPY DQLAALST SEPTKEQLTR YGPYSQTKETVPVKEPGQPDEHESTSTV MSVLAPP ETVSVGIQADGP FQV DESSDESQLG213C1LCL305505SV GISI L TITT TGTSC HGKPFLS T DTKTNSSAEASW EDC H G S NC W DAC AGLVLSE FV D K QKEYRTMELH CLSIY QSWT GL LVSGSYSSAGS SSV V A KSVH I E WFMSLGTV GKSVMYV A TPKPV N HLVPAE EFSVSR K GFRATWSSTLKTTVT T LAVTD G G VV TLP RSV A G CLS PGDV DPEG VAS ATV GAVPG GV VL CT E LVVAPP IDDSSFG A KEML EP PRQSDMAT STSN VKST LE VEGSV KL SNT PDLV K N GGQ PPRVSA R GPFPFKKGS SNPPD YYK V DLY V YV RI LS ATQK WSL SPATV V RSV V VFPGSLVW ASYSDLG WPVGSP SNSWISPVSTYKPLH C R PSY Y K Q GPQ PIWTSCPEKTQS LN Y N YPK T M Y G WLSG G MYIQD KVLG W YSY NSLAFAV LPGESNCML NFN KR VLKRK G D YLT TSC YTIKAPE SV NT TK YYE PCYSQ SYSNSYTV AGQLNSGLSGFPFQ CIHD V Q K Q GTLN KTYES SSLSGSLAQI SLK VSYLYTKK EPEEG KSNED V HVL FSN VSVAVS SQ V GYNPD V ATDPKD R NLA VPTN QTF ISK DT TIG G KQE PQ Q WSN GLKHLVE S SA R V N AVTG Q G R K V K VPF TCSPPH KK GG213C1C H H95340B49BG9G V VATTORNEY DOCKET NO. JBI6882WOPCT1 805P KD QV S ES SQEPDE LQLS QYLSG Q WS PSPN AI FI G HTLTYL F SQVRTVSL EC SF PA IETA N A A Y G QG VD V V K SSGTK H A RSR C GKIWKTS EQEY FFTRLV K D SR AA VP TGEKR V DG Q RP SL SSF YTG VSQL T FLYNTATSS PNSL AYSLSLLSCFVILC YESP YSILQ VTQ VQL S SGRTNCYAD TKN SFSMPY GDKV A IT SQTER GAFKLETVP41CL705SSPLNPD SATV V K NLTSPDF L V K S GFWEDCFS V A SSA TPKSV A Q V KPV NH KS P PR YVR SYYV NPT LK YT T L TD G V HL EIYK CSIY V VFPGSCTATIA V G A V V GC VVPLHPPWTK Q GPQLSLKT A M G GVK LL T ETAG NCMNF SCPKTTQLTGL T T S SSTE VVLPSVTLTK N KEVK WSL P RSD GTNSNP EGVLSNHD V YY RP LYRKT PKVQSW L S A PDSAQLCTK EQECNSQQ QLPGKS S S P P TV R V K VVIA YK DPP TC KPDEEK QTG GLSN KTT RED YP I SDW S V YK CSY RNWPMI P T LHPP IW YSVF QS PT TKPEFH RSPNK KLA VPV H KSN D AV WKQ QTNVLG YIT F LPG ESN S VCM TL NFTSK CHGVLP LFVTDSIN GLHKNKLTV P GTM APHT DFPFQLN CIHTTD K N V Y K YG SES SV V D K S V A QTHKTSSEYAG V DL RLESGSN VLV ESY P D V AYTKKDPEPQ EEKT SL PK KPV N G V HL EVIM PEEWE FH FEM KTTWV G KPLQ WQ C KPDEG K KV FT T SPER NAVTDG C VV VL T ETARVSV LVLPL SAIGS T LINTLHGKFHP LVSF LK D RSCLP LSKGSVKTLEVEGVSAPPD C A S A GVSE FVTW DS SQ GL TAS LGSV V D K D 41C H 074B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 016537L Q A VS VQ PDQQP PCK QEYLASS SPEW G A D Y Q YLK TIIAKPASRD YLSQ KRH WSIG WSALTD V K SLA VYLSTATT VTWSFGIGNS LQSDKVEPVTSS KTATSGSS SG G GGLQGPTS Y SSGSCFGF F LA G S RDY R CSI DVSSP VIS S FL R T V YLATD V R GGC ASAPIQSGP SVLY KCEREGTPR MSTNTS ANPGPA ANGSKSASR S N D N QV L SSV GYSA Q K SYPIQSTKSLA G CLPLE PTE TGYIQLY YET KS TV LPT T PSLDSP E SQLVG T RV A A PPS T E FGEHLV A PDE TA KTQ QG LVIEG 516C1LCL905537TMSY E SGT RTP K H LI E FA WEELHVT ID AVTAT LAVTD G VEWFM C WVCC VVP EESVSAEY V GGG V VLT ETLAP RSV G D C CLREFSV T DL SYLPTGSVKLVV GVLP AI SSKSLGSV GS LPAIDCSGMV GST NSTEP EPDSAPL DDFK V G RLDSSFTSKLTKTG VATQSWSGKSLN SSPAP TV V K R YV NTSP LP L GPSYYV N P GSLSAYPDYLV GEA RSDSV YK CSIWRG Y V VF PQSV NPSSP PKA WGQ YSP T LHPPMN T KQ GTQLPRVFPGLK Q RLA D AVPGSNC LF S CPKTWSK K VQPGPQSVISP TVF L E SVT TK N KERVK YR Q VWEKTTQLS LY NSY PFPFQNHD V YYP LC NS T LARPVLK W KGPN YTLV YLCI TKPEPQEQTN K Y G MQCGTYRNSQG WNLA KTSYTKLSSSPD VYK DK D EEK GL ED H G A G KAP TCP ERG KS PVTN GS YKLN D YEY NS SK VF QASET SPFHPNLA V QLHE TPV HQ GSGF SDT LTG KLSK KSQ N GKLAV SFKVSQ QTNLQIITN GLHK NKS LVSTTQS CHL PDFN W AGA Q GIRKSRESS LVS E FV DTW K DIV V V A QTKN TSSEYE LTH QFAGSSSKSPV N HKEM WLFMVEGS516C1C H H 298931B19BG9G V VATTORNEY DOCKET NO. JBI6882WOPCT1 837ESSESLP D ES SDEE LPQPSG K Q QPDSPQSG QFNIFG HSTQ Q YLSPSFN IVFG HSTS Q VEWIQ VEP LV TV A CL LSP LA CA N A HTFA AA D Y NDN A YV VSI TD VTV K GGV V KRK HSTR K HKIWK QSGWKEQEV Y ASKIQEG D V YVKK D RSVTAACT FKK D AGEGR KPSILTR VSTAPGEKPRSLGFYF TLRV DGGPFYTLTLNTGS T F TNS V Q FNSP LS S L PNSSLAT A L LRL SCS S L SG C V Y TESLA N C V YCTEYSG SA YSGHVR SYKVRQSA D K NPS ILQSA D K NCT SFLCSFY DSQ KYT SYGVSQKTTMPY GSD QKTA KF LEQTVQVPS IV KTAKD G VLEV QTVPS71CL737DC AGVSE F K DITKN SAADCSSLGSSVRSIYSYS LGVAS STSV P K VSD A V Q KPNKTSYEA WRVSYVASTPK HHL EMELH CEAL IYTAT LVKTFVTAT LVD G VVVIPEEWFFMLGTFV V G ATD VRAGTV G ATV GCETAREVSVSR K RAD LTG GTLS V VK LL TVLPSAG CLSGTG GSVKP GDGSV NSTKEGSSTNSTE VEGVS LAPP IDSSFG A KEQTS SNVA QSWSNSPPD V KLDS DV KGQVSD GK WSLSSPD R GKSLS PAP TVV NT P LN GPPR D R L WSV YKALSWSS V YK C RSYR SYYFV GSQEV VSYSP T LHY N YP T LHPP IW N Y V V Q GPPQLS LW Y ND AVPG NFIMD AVPG NCMFTSK CPKTQLG N YIMF L ESSVY QFGLPESSVTLTK N KEVTWSGMTQYPFP QNDSLGFPNSF FQ C HD V YY RP LKRSK GSRLD VFYLCISLSLEVSYL I TPK ED VYTKP PQ EEK QCY KQGTLNTSN D YEYSSYLMSD VYVRSS SGPG KATSIN WSSK D G KAA R KVPLF QD KDTTCSPE EG KSPH RPNA VEPVTH NL FSQIF IN Y H KSEKT VPLF QTTG LP L S LQ Q VTWSN GLKL E S SA R V N ASC H V N ATSC HG K F K K H V GA G VLS71C H 4421B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 047P D ES SKEPDE LSQSG QPQ Q QPN YLS FI G HTWSF SVAITVQL EL LSYTPA C A RFA N Y NIETA D V V V K GGTK QSSGR H WKASKIQER GELV Y CSTIFTRKK D STAEA KVPGRSRV QLGP TDG YSFFLG VQTS LYNTPNSLSATSSYLLSLATC YCEFSANLVT GP YIQVS RSL QSD N QLT KCA KYTLP GSFDSQI TYKT SK QKETV D GAF LQTVPS81CL937VSD K DIPV A QTKNAVD VLGS V V D K DI KNG V NH KTSSEA W MEYLH CERLSI CSYSASSKSV A QTVA TTSLPKPV NH KMEG V HL EI E WFMSGT YT TVL C VVP E EF VLKF IV G A GTD G V HL EIV V GE WL C VVP E EL T ETLARVS SRGRATT GSVKL T ETLARVEPVVPL SAIG CLS PGT ST NSTE VVPL SAIAEPPGVT DSAPVPDLDSSSFK G A KDG G QAEQS SNP EGVK WSL S A PTDSAPVPL DSC R VPPSIYVKT PDRNSYYLV N GPS PRSA K V DRGSLWS VS P PTYK C R V K S YV NTSYPYCM WTL NY FTV VFVPGLS K Q GPQSVLW ASVPVLHPN YIA PG CPKTQLGYIM DLPESNP ISVCM WRV TL NY FTVFSK Q G CPKHTTD K N V Y KEVTWSG M YQMFPFQN CHTK N KEVKKPEQY REP LK C YRSK Q GNFSLG VL I TD V Y TSKSY YSY VYKKPEQY RLE PCDCSKPPD EPE EK QTN KER G GLNKSN D Y VS SFSLSSYPDATD NGG KPQ C KPPD EEK QTG GLVEPV HL TIKPKV FT T SPER NKSKFHS P LA Q QTLNE FYSY ATLG KFHP LA VPELFVKTWKSN G KHLVEGSG V N RSC H A G VLSPELF SVKTWKSQ N 81C H 4521B9G VATTORNEY DOCKET NO. JBI6882WOPCT1244747PDESESPDESKEDLKEDEQP S QG QP QQEYLPWRPSFN QSI G HQ YELPPSNA SI F S TWR FI GSLTVYLS Q VEA SI FVQPLSTA A CLTAYLSLSTPASFN YSFA NSDAVTV D V VSGKSDTA D V V STR K HVSGSTR KQSGKASIW QKEQSGK W I QR GEV V Y ASD G GEVC S KKC SV KS FAAS FK ALRTD GERKSLR DTGETAPIG GPLTRT APIGPREGT FYFL REG GFYFGPATLNTSR NSTSG ATLN NL R PLL L PSRS PSLS SLA RLG CSYC LS SRLCTG Y VTEGLA GGFVGYPIHVS SDR TGYIQVSSLQ N CA K F PSLQ CAQLT RYTL PGSDSK QLR YTG A YSTKQT L PA YSVIEQ V GAF LEQTV VPV SIEQ VKGAF LQ910C2LCL143747A L S V K DIA W RFYSCESAGSSV D KSV A QTKTNSL ISSAEAES V Y T Y F VVTATTL PV KPV N D G V HHLKEIMEYLH CLFGTV MSKFLGARAG ATG VPE W FLRTR KLGTVL G GV VSGPKDE T SK L CTVETAEREVSVSRGPGDETSV NST LE VVLPL SAG CLSA K AG AVA G QSWSNP EPGVSAPP IDDSSFK GQ VSRGPQSD RLGKSLSSPAP TD V V KL S DV G GRV DLSQR SV ASW S VTYK C RSYV NTSYPYLNPA K A NVY NP PLWSY VLH G NPP IWRY V VFVPGSW Y QL VAFM T MDFALP SVCM LN TK Q GPTQSLLMIY HGG MSQLGPEPSG A G Y GFSVFQNT T FLCIHTD KSN CPEKTG WSG AN LFV Y KVY RLKRK GYS SLSEYLSGLSSLF GTTESY D VYKKPEQE PCYSQN QP TS S TSN G KAT SIKD KVP TD FQTCSKPPD EK Q EEGTLN K D YER G KSNEV HVFSLTF ISK AQFAS SK NTS LCTPH G KFHPNLA VPTN QGSV NVEGSA V D C A G VLSPELF SVKTQ Q WKS LH VSD N G KL EA W R910C2C H H7083413B19BG9G V VATTORNEY DOCKET NO. JBI6882WOPCT1 647SLPS SG KDEE LQEPDQGQHQESP STYL PN QVWR FI G HSTEA SI FQ VCLTVSL ECAYLTPA AYTSFA N D YVSDTA V VKVV KHG TKKSEQSSGRH K WY ASIEQKEV YD R G CSV K DAKS FASLRK ALTDT EKSTAPGLIGRPLTR G YTSEGSGT FTFLNTSL PAS SRLN SPSSLYCLLTELS SA RSCSG LG C YEDR TG VTYYVSGRKN GPILQ QSA D K NSFS L T SFDSQR CFDSQK TET L PA YGSQKTTV V VK EV VPSIEQ GAF LQTVPS12CL547S SS SV A Q T A D C HP LSVATPKPV NH KMSEY E W H AER C S AGV LSE FVTAT LVK D G V HL EI E W LFCLSIYSLGSV V DV G ATV V GL C VVP E EFM VSGT YL SASSKSPVLTGSGSVKL T ETARNSTE VVLVPL SVSPAS LKFA V A TL PIG C RL GRT TVTAVK T D G V G VGQTS SNP EGK WSLSS A PG T DSAPV KLDDSSSDFKS PGDG A KELG TGSGSV VL CVKT L TVWSYSPVTYP PLK C R V VNT P LV GP GQVSA GTNSNEP EHP SIY RSYYV N GS PR D R QSWSS A PDF AV GP LP SNPM W Y V V QFPQLK VSLSGKSLS P P TPEVC L N TKPGPT QSLVW Y N WSS V YK C R PSNT T F SCEKT S LYFIMYP T LHP SIGF FQLC HTD K N KR VLK W K G M YQEAV G NPC MA V Y VIV Y KK E YPCYRSQG A DLFLPESVTLV SPDA YDP PQ EEQTN KTGSY N YPPFPSNHTSG KP TCK DEK GLN D YENG LGSVFQLCI TDDRKV F QT S PPERG KSEV HV SF S S ISY VYKKPATL TGKFHPNLACSC H VLPELF SVK KVPSQ QTLN HLQTFSIN H S K DPD G KATPQD CKPYASGLGSSV V DTW K DITN G K NKS LAVEGS SA R V N AKTVLFT TGSKPF12C H 3561B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 847GPF D ESESLK DQG QEPSP SQ Q QPN GHYLFIS TWSVA SI FQELTVSLC YL PA STN A F A D Y SIEA V V K VTV QSGSTK R H WKARKIQERSY CEV G TI SV K D FK AA T R VRST EKP GRSQPLYTD V G GG FFLTVS TNSSQ WNLSAL PS N LS YLLCSYCEFT SVTSPVN VSGRSYLIQSD N QL Q A K FTL C T S SLKYGSDKQI PAYQTTK EV D K ALQTVPS22CL747TINAS K Y T T T EPK DTKQKTSS E YEV EHT LSAIYT T V G A V VLV LLSP AIDG GVKLE VEGVSAPDSANHELIM PEEW LEFFM CTV TLKLA MS SNST PPD KL S DG RT TTSL N ATV VNT P LH V ARVS ST PN D GSWSSPPR Y V RSYYFVVETLPL SAG CL PKVQKSYKCSIW Y V V GPPVV PGSAP ID S TQLPGSL DS FKERI SDW S VLP TG HPNPC ML NFT KQ SCPKTVTD V KTSV VNSYPDV GT TMIAV YLNPPWSN DLPESSVT TK N KE LK NHD V YY RPCYY R V VFV Y Q GPGSPQLK NYSVT FPL MSP Q CTK EQEQTN K M AF F L IKP PEK GLNWTK CPKTQL VGETD VSY VYDK DEG KSENSKEVTWS PMDLRPDAP TCP ER NLA VPFNY RLKRK GRNVLEG KF QSPFHPKQ QK YE PCYSQ SASV KVT TG KLSVKTWSN GV Q K QTN KT ENFIQWTLHLPE FDITKNEPEG GLDE SN D Y KSHSKSC VSD K V V QKTSEERPNK L A VEQPV HLQTLNT LAK N AGVSLSRSLGS SSKSPV A V NHL EIM EWH K WKSN G KHLQFG WTA D CSA V ATL PK G V H V D G C VVT PAEREV 22C H 1071B9G VATTORNEY DOCKET NO. JBI6882WOPCT1 CSFV KN GGPSQLQSWLRSSKKQDTYVTHLNK HS LYALEFHFSM GVSATTORNEY DOCKET NO. JBI6882WOPCT1

[0075] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence set forth in Table 7, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NOs: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0076] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence set forth in Table 7, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the light chain comprises the amino acid sequence set forth in SEQ ID Nos: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0077] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence set forth in Table 7, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence set forth in Table 7, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the heavy chain comprises the amino acid sequence set forth in SEQ ID NOs: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and the light chain comprises the amino acid sequence set forth in SEQ ID Nos: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0078] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence set forth in Table 7; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence set forth in Table 7. In some embodiments, the heavy chain comprises the amino acid sequenceATTORNEY DOCKET NO. JBI6882WOPCT1 set forth in SEQ ID NOs: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and the light chain comprises the amino acid sequence set forth in SEQ ID Nos: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0079] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising a sequence set forth in any one of SEQ ID NOs: 723, 725, 729 or 733 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0080] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprises an amino acid sequence set forth in any one of SEQ ID NOs: 724, 726, 730 or 734 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0081] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragmentATTORNEY DOCKET NO. JBI6882WOPCT1 thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising a sequence set forth in any one of SEQ ID NOs: 723, 725, 729 or 733 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence set forth in any one of SEQ ID NOs: 724, 726, 730 or 734 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0082] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence set forth in Table 6; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence set forth in Table 6.

[0083] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising an amino acid sequence set forth in any of Tables 1-5, a heavy chain CDR2 comprising an amino acid sequence set forth in any of Tables 1- 5, and a heavy chain CDR3 comprising an amino acid sequence of set forth in any of Tables 1-5.

[0084] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising an amino acid sequence set forth in any one of SEQ ID NOs: 517, 523, 535, 547, 559, 565, 577, 589, 601, 607, 619, 631, 643, 649, 661, 673, 685, 691, 703 or 715; a heavy chain CDR2 comprising an amino acid sequence set forth in any of SEQ ID NOs: 518, 524, 536, 548, 560, 566, 578, 590, 602, 608, 620, 632, 644, 650, 662, 674, 686, 692, 704 or 716; and a heavy chain CDR3 comprising an amino acid sequence of set forth in any of SEQ ID NOs: 519, 525, 537, 549, 561, 567, 579, 591, 603, 609, 621, 633, 645, 651, 663, 675, 687, 693, 705 or 717.

[0085] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprisesATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising an amino acid sequence set forth in Table 1, a heavy chain CDR2 comprising an amino acid sequence set forth in Table 1, and a heavy chain CDR3 comprising an amino acid sequence of set forth in Table 1; a heavy chain CDR1 comprising an amino acid sequence set forth in Table 2, a heavy chain CDR2 comprising an amino acid sequence set forth in Table 2, and a heavy chain CDR3 comprising an amino acid sequence of set forth in Table 2; a heavy chain CDR1 comprising an amino acid sequence set forth in Table 3, a heavy chain CDR2 comprising an amino acid sequence set forth in Table 3, and a heavy chain CDR3 comprising an amino acid sequence of set forth in Table 3; a heavy chain CDR1 comprising an amino acid sequence set forth in Table 4, a heavy chain CDR2 comprising an amino acid sequence set forth in Table. 4, and a heavy chain CDR3 comprising an amino acid sequence of set forth in Table 4; or a heavy chain CDR1 comprising an amino acid sequence set forth in Table 5, a heavy chain CDR2 comprising an amino acid sequence set forth in Table. 5, and a heavy chain CDR3 comprising an amino acid sequence of set forth in Table.5.

[0086] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 selected from the group consisting of any of the heavy chain CDR1 set forth in Tables 1, 2, 3, 4, and 5, and variants having conservative modifications thereof.

[0087] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR2 selected from the group consisting of any of the heavy chain CDR2 set forth in Tables 1, 2, 3, 4, and 5, and variants having conservative modifications thereof.

[0088] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR3 selected from the group consisting of any of the heavy chain CDR3 set for in Tables 1, 2, 3, 4, and 5, and variants having conservative modifications thereof.

[0089] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising an amino acid sequence set forth in any of Tables 1-5, a light chain CDR2 comprising an amino acid sequence set forth in any of Tables 1-5, and a light chain CDR3 comprising an amino acid sequence set forth in any of Tables 1-5.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0090] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising an amino acid sequence set forth in Table 1, a light chain CDR2 comprising an amino acid sequence set forth in Table 1, and a light chain CDR3 comprising an amino acid sequence set forth in Table 1; a light chain CDR1 comprising an amino acid sequence set forth in Table 2, a light chain CDR2 comprising an amino acid sequence set forth in Table 2, and a light chain CDR3 comprising an amino acid sequence set forth in Table 2; a light chain CDR1 comprising an amino acid sequence set forth in Table 3, a light chain CDR2 comprising an amino acid sequence set forth in Table 3, and a light chain CDR3 comprising an amino acid sequence set forth in Table 3; a light chain CDR1 comprising an amino acid sequence set forth in Table 4, a light chain CDR2 comprising an amino acid sequence set forth in Table 4, and a light chain CDR3 comprising an amino acid sequence set forth in Table 4; or

[0091] a light chain CDR1 comprising an amino acid sequence set forth in Table 5, a light chain CDR2 comprising an amino acid sequence set forth in Table 5, and a light chain CDR3 comprising an amino acid sequence set forth in Table 5.

[0092] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 selected from the group consisting of any of the light chain CDR1 set forth in Tables 1, 2, 3, 4, and 5, and variants having conservative modifications thereof.

[0093] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR2 selected from the group consisting of any of the of the light chain CDR2 set forth in Tables 1, 2, 3, 4, and 5, and variants having conservative modifications thereof.

[0094] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR3 selected from the group consisting of any of the light chain CDR3 set forth in Tables 1, 2, 3, 4, and 5, and variants having conservative modifications thereof.

[0095] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH1 set forth in Table 1, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL1 set forth in Table 1.

[0096] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH2 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL2 set forth in Table 1.

[0097] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH3 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL3 set forth in Table 1.

[0098] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH4 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL4 set forth in Table 1.

[0099] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH5 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL5 set forth in Table 1.

[0100] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH6 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL6 set forth in Table 1.

[0101] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH7 set forth in Table 1, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL7 set forth in Table 1.

[0102] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH8 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL8 set forth in Table 1.

[0103] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH9 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL9 set forth in Table 1.

[0104] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH10 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL10 set forth in Table 1.

[0105] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH11 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL11 set forth in Table 1.

[0106] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH12 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL12 set forth in Table 1.

[0107] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH13 set forth in Table 1, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL13 set forth in Table 1.

[0108] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH14 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL14 set forth in Table 1.

[0109] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH15 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL15 set forth in Table 1.

[0110] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH16 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL16 set forth in Table 1.

[0111] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH17 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL17 set forth in Table 1.

[0112] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH18 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL18 set forth in Table 1.

[0113] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH19 set forth in Table 1, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL19 set forth in Table 1.

[0114] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH20 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL20 set forth in Table 1.

[0115] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH21 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL21 set forth in Table 1.

[0116] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH22 set forth in Table 1, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL22 set forth in Table 1.

[0117] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH1 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL1 set forth in Table 2.

[0118] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH2 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL2 set forth in Table 2.

[0119] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH3 set forth in Table 2, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL3 set forth in Table 2.

[0120] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH4 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL4 set forth in Table 2.

[0121] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH5 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL5 set forth in Table 2.

[0122] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH6 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL6 set forth in Table 2.

[0123] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH7 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL7 set forth in Table 2.

[0124] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH8 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL8 set forth in Table 2.

[0125] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH9 set forth in Table 2, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL9 set forth in Table 2.

[0126] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH10 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL10 set forth in Table 2.

[0127] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH11 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL11 set forth in Table 2.

[0128] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH12 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL12 set forth in Table 2.

[0129] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH13 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL13 set forth in Table 2.

[0130] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH14 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL14 set forth in Table 2.

[0131] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH15 set forth in Table 2, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL15 set forth in Table 2.

[0132] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH16 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL16 set forth in Table 2.

[0133] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH17 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL17 set forth in Table 2.

[0134] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH18 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL18 set forth in Table 2.

[0135] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH19 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL19 set forth in Table 2.

[0136] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH20 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL20 set forth in Table 2.

[0137] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH21 set forth in Table 2, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL21 set forth in Table 2.

[0138] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH22 set forth in Table 2, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL22 set forth in Table 2.

[0139] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH1 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL1 set forth in Table 3.

[0140] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH2 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL2 set forth in Table 3.

[0141] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH3 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL3 set forth in Table 3.

[0142] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH4 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL4 set forth in Table 3.

[0143] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH5 set forth in Table 3, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL5 set forth in Table 3.

[0144] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH6 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL6 set forth in Table 3.

[0145] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH7 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL7 set forth in Table 3.

[0146] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH8 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL8 set forth in Table 3.

[0147] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH9 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL9 set forth in Table 3.

[0148] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH10 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL10 set forth in Table 3.

[0149] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH11 set forth in Table 3, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL11 set forth in Table 3.

[0150] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH12 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL12 set forth in Table 3.

[0151] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH13 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL13 set forth in Table 3.

[0152] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH14 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL14 set forth in Table 3.

[0153] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH15 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL15 set forth in Table 3.

[0154] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH16 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL16 set forth in Table 3.

[0155] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH17 set forth in Table 3, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL17 set forth in Table 3.

[0156] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH18 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL18 set forth in Table 3.

[0157] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH19 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL19 set forth in Table 3.

[0158] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH20 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL20 set forth in Table 3.

[0159] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH21 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL21 set forth in Table 3.

[0160] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH22 set forth in Table 3, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL22 set forth in Table 3.

[0161] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH1 set forth in Table 4, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL1 set forth in Table 4.

[0162] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH2 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL2 set forth in Table 4.

[0163] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH3 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL3 set forth in Table 4.

[0164] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH4 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL4 set forth in Table 4.

[0165] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH5 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL5 set forth in Table 4.

[0166] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH6 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL6 set forth in Table 4.

[0167] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH7 set forth in Table 4, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL7 set forth in Table 4.

[0168] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH8 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL8 set forth in Table 4.

[0169] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH9 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL9 set forth in Table 4.

[0170] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH10 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL10 set forth in Table 4.

[0171] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH11 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL11 set forth in Table 4.

[0172] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH12 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL12 set forth in Table 4.

[0173] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH13 set forth in Table 4, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL13 set forth in Table 4.

[0174] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH14 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL14 set forth in Table 4.

[0175] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH15 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL15 set forth in Table 4.

[0176] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH16 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL16 set forth in Table 4.

[0177] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH17 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL17 set forth in Table 4.

[0178] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH18 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL18 set forth in Table 4.

[0179] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH19 set forth in Table 4, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL19 set forth in Table 4.

[0180] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH20 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL20 set forth in Table 4.

[0181] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH21 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL21 set forth in Table 4.

[0182] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH22 set forth in Table 4, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL22 set forth in Table 4.

[0183] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH1 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL1 set forth in Table 5.

[0184] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH2 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL2 set forth in Table 5.

[0185] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH3 set forth in Table 5, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL3 set forth in Table 5.

[0186] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH4 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL4 set forth in Table 5.

[0187] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH5 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL5 set forth in Table 5.

[0188] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH6 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL6 set forth in Table 5.

[0189] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH7 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL7 set forth in Table 5.

[0190] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH8 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL8 set forth in Table 5.

[0191] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH9 set forth in Table 5, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL9 set forth in Table 5.

[0192] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH10 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL10 set forth in Table 5.

[0193] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH11 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL11 set forth in Table 5.

[0194] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH12 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL12 set forth in Table 5.

[0195] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH13 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL13 set forth in Table 5.

[0196] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH14 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL14 set forth in Table 5.

[0197] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH15 set forth in Table 5, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL15 set forth in Table 5.

[0198] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH16 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL16 set forth in Table 5.

[0199] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH17 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL17 set forth in Table 5.

[0200] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH18 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL18 set forth in Table 5.

[0201] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH19 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL19 set forth in Table 5.

[0202] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH20 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL20 set forth in Table 5.

[0203] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH21 set forth in Table 5, and the amino acid sequences ofATTORNEY DOCKET NO. JBI6882WOPCT1 the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL21 set forth in Table 5.

[0204] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2, and the heavy chain CDR3 corresponding to VH22 set forth in Table 5, and the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 corresponding to VL22 set forth in Table 5.

[0205] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a light chain variable region (VL) comprising an amino acid sequence of any one of SEQ ID NOs: 724, 726, 730 or 734, set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0206] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence set forth in Table 6; and / or a light chain variable region (VL) comprising an amino acid sequence set forth in Table 6.

[0207] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence encoded by a nucleotide sequence which can encode any of the VH sequences set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a light chain variable region (VL) comprising an amino acid sequence encoded by a nucleotide sequence which can encode any of the VL sequences set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0208] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence encoded by a nucleotide sequence which can encode any of the VH sequences set forth in Table 6; and / or a light chain variable region (VL) comprising an amino acid sequence encoded by a nucleotide sequence which can encode any of the VL sequences set forth in Table 6.

[0209] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence corresponding to VH1 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL1 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH2 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL2 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH3 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL3 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH4 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL4 set forth in Table 6, or a sequence having at leastATTORNEY DOCKET NO. JBI6882WOPCT1 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH5 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL5 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH6 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL6 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH7 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL7 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH8 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL8 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH9 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL9 set forth in Table 6, or a sequence having at leastATTORNEY DOCKET NO. JBI6882WOPCT1 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH10 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL10 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH11 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL11 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH12 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL12 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH13 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL13 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH14 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL14 set forth in Table 6, or a sequence having at leastATTORNEY DOCKET NO. JBI6882WOPCT1 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH15 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL15 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH16 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL16 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH17 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL17 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH18 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL18 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH19 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL19 set forth in Table 6, or a sequence having at leastATTORNEY DOCKET NO. JBI6882WOPCT1 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH20 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL20 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence corresponding to VH21 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL21 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; or a heavy chain variable region comprising an amino acid sequence corresponding to VH22 set forth in Table 6 , or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence corresponding to VL22 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0210] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence corresponding to VH1 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL1 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH2 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL2 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH3 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL3 set forth in Table 6;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence corresponding to VH4 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL4 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH5 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL5 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH6 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL6 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH7 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL7 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH8 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL8 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH9 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL9 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH10 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL10 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH11 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL11 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH12 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL12 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH13 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL13 set forth in Table 6;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence corresponding to VH14 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL14 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH15 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL15 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH16 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL16 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH17 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL17 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH18 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL18 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH19 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL19 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH20 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL20 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence corresponding to VH21 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL21 set forth in Table 6; or a heavy chain variable region comprising an amino acid sequence corresponding to VH22 set forth in Table 6, and a light chain variable region comprising an amino acid sequence corresponding to VL22 set forth in Table 6.

[0211] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH1 set forth in Table 6,ATTORNEY DOCKET NO. JBI6882WOPCT1 and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL1 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH2 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL2 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH3 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL3 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH4 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL4 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH5 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL5 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH6 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL6 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH7 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL7 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH8 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL8 set forth in Table 6;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH9 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL9 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH10 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL10 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH11 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL11 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH12 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL12 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH13 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL13 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH14 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL14 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH15 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL15 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH16 set forth in Table 6,ATTORNEY DOCKET NO. JBI6882WOPCT1 and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL16 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH17 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL17 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH18 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL18 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH19 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL19 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH20 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL20 set forth in Table 6; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH21 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL21 set forth in Table 6; or a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence corresponding to VH22 set forth in Table 6, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence corresponding to VL22 set forth in Table 6.

[0212] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH1 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such asATTORNEY DOCKET NO. JBI6882WOPCT1 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL1 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH2 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL2 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH3 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL3 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH4 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL4 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH5 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variableATTORNEY DOCKET NO. JBI6882WOPCT1 region corresponding to VL5 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH6 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL6 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH7 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL7 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH8 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL8 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH9 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL9 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH10 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL10 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH11 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL11 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH12 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL12 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH13 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL13 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH14 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such asATTORNEY DOCKET NO. JBI6882WOPCT1 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL14 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH15 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL15 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH16 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL16 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH17 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL17 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH18 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variableATTORNEY DOCKET NO. JBI6882WOPCT1 region corresponding to VL18 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH19 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL19 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH20 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL20 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH21 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL21 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; or a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a heavy chain variable region corresponding to VH22 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL22 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0213] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH1 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL1 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH2 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL2 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH3 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL3 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH4 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL4 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH5 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL5 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH6 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by aATTORNEY DOCKET NO. JBI6882WOPCT1 nucleotide sequence which can encode a light chain variable region corresponding to VL6 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH7 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL7 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH8 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL8 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH9 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL9 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH10 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL10 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH11 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL11 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH12 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by aATTORNEY DOCKET NO. JBI6882WOPCT1 nucleotide sequence which can encode a light chain variable region corresponding to VL12 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH13 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL13 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH14 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL14 set forth in Table 6;a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH15 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL15 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH16 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL16 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH17 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL17 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH18 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL18 set forth in Table 6;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH19 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL19 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH20 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL20 set forth in Table 6; a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH21 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL21 set forth in Table 6; or a heavy chain variable region comprising an amino acid sequence encoded by a nucleotide which can encode a heavy chain variable region corresponding to VH22 set forth in Table 6, and a light chain variable region comprising an amino acid sequence encoded by a nucleotide sequence which can encode a light chain variable region corresponding to VL22 set forth in Table 6.

[0214] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 481, 483, 485, 487, 735, 737, 739, 741, 743, 745, or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743, or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0215] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC)ATTORNEY DOCKET NO. JBI6882WOPCT1 comprising an amino acid sequence of SEQ ID NO: 482, 484, 486, 488, 736, 738, 740, 742, 744, 746, or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744, or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0216] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 741, 743, 739, 747, 485, 483, 735, 737, or 745, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743, or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0217] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 742, 744, 740, 748, 486, 484, 736, 738, or 746, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen- binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0218] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: or 737, 739, 743 or 747 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of aATTORNEY DOCKET NO. JBI6882WOPCT1 heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 741, 743, 739, or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 742, 744, 740, or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0219] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 481, 483, 485, 487, 735, 737, 739, 741, 743, 745, or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 482, 484, 486, 488, 736, 738, 740, 742, 744, 746, or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0220] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 485, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identityATTORNEY DOCKET NO. JBI6882WOPCT1 thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 486, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0221] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 737, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0222] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 739, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 740, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0223] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 743, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 744, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0224] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 747, or a sequence having at leastATTORNEY DOCKET NO. JBI6882WOPCT1 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0225] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain HC comprising an amino acid sequence of SEQ ID NO: 481, 483, 485, 487, 735, 737, 739, 741, 743, 745, or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 482, 484, 486, 488, 736, 738, 740, 742, 744, 746, or 748.In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain HC comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748.

[0226] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain HC comprising an amino acid sequence of SEQ ID NO: 741, 743, 739, 747, 485, 483, 735, 737, or 745; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 742, 744, 740, 748, 486, 484, 736, 738, or 746. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain HC comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748.

[0227] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain HC comprising an amino acid sequence of SEQ ID NO: 743 or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 744 or 748.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0228] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 451, 453, 455, 457, 721, 723, 725, 727, 729, 731, or 733 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0229] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 727, 729, 725, 733, 455, 453, 721, 723, 731, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747 or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0230] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0231] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 728, 730, 726, 734, 456, 454, 722, 724, 732, or a sequence having at least 80%, 85%, 90%, preferably 95% or more,ATTORNEY DOCKET NO. JBI6882WOPCT1 such as 95%, 96%, 97%, 98%, or 99% identity thereto. In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0232] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 451, 453, 455, 457, 721, 723, 725, 727, 729, 731, or 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0233] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0234] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 727, 729, 725, 733, 455, 453, 721, 723, 731, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 728, 730, 726, 734, 456, 454, 722, 724, 732, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0235] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0236] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 727, 729, 725, or 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 728, 730, 726, or 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0237] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0238] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 451, 453, 455, 457, 721, 723, 725, 727, 729, 731, or 733; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0239] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748.

[0240] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 727, 729, 725, 733, 455, 453, 721, 723, 731; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 728, 730, 726, 734, 456, 454, 722, 724, 732.

[0241] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748.

[0242] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 727, 729, 725, or 733; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 728, 730, 726, or 734.

[0243] In some embodiments, the isolated antibody, or antigen-binding fragment thereof, comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 737, 739, 743 or 747; and a light chain CDR1, a light chain CDR2, and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 738, 740, 744 or 748.

[0244] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 19, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 21; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 511, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 512, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 513; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 517, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 519; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 523, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 524, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 525; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 529, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 530, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 531; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 535, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 536, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 537; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 541, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 542, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 543; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 547, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 548, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 549.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0245] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 517, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 518, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 519; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 523, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 524, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 525; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 535, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 536, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 537; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 547, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 548, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 549.

[0246] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 93; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 97, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 98, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 99; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 103, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 104, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 105; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 109, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 110, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 111; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 553, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 554, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 555;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 559, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 560, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 561; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 565, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 566, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 567; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 571, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 572, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 573; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 577, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 578, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 579; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 583, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 584, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 585; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 589, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 590, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 591. In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 181, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 182, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 183; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 187, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 188, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 189; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 193, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 194, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 195; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 199, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 200, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 201;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 595, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 596, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 597; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 601, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 602, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 603; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 607, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 608, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 609; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 613, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 614, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 615; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 619, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 620, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 621; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 625, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 626, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 627; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 631, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 632, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 633.

[0247] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 559, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 560, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 561; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 565, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 566, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 567;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 577, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 578, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 579; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 589, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 590, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 591. In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 601, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 602, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 603; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 607, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 608, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 609; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 619, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 620, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 621; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 631, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 632, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 633. In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 271, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 272, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 273; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 277, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 278, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 279; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 283, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 285;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 289, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 290, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 291; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 637, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 638, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 639; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 643, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 644, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 645; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 649, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 650, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 651; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 655, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 656, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 657; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 661, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 662, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 663; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 667, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 668, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 669; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 673, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 674, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 675. In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 643, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 644, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 645; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 649, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 650, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 651;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 661, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 662, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 663; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 673, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 674, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 675.

[0248] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 361, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 362, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 363; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 367, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 368, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 369; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 373, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 375; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 379, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 380, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 381; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 679, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 680, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 681; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 685, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 686, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 687; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 691, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 692, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 693;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 697, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 698, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 699; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 703, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 704, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 705; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 709, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 710, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 711; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 715, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 716, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 717.

[0249] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 685, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 686, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 687; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 691, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 692, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 693; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 703, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 704, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 705; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 715, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 716, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 717.

[0250] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 13, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 15;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 103, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 104, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 105; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 193, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 194, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 195; a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 283, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 284, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 285; or a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 373, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 374, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 375.

[0251] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 1, 7, 13, 19, 511, 517, 523, 529, 535, 541, 547, 91, 97, 103, 109, 553, 559, 565, 571, 577, 583, 589, 181, 187, 193, 199, 595, 601, 607, 613, 619, 625, 631, 271, 277, 283, 289, 637, 643, 649, 655, 661, 667, 673, 361, 367, 373, 379, 679, 685, 691, 697, 703, 709, and 715, and variants having conservative modifications thereof.

[0252] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 559, 565, 577 and 589, and variants having conservative modifications thereof.

[0253] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 2, 8, 14, 20, 512, 518, 524, 530, 536, 542, 548, 92, 98, 104, 110, 554, 560, 566, 572, 578, 584, 590, 182, 188, 194, 200, 596, 602, 608, 614, 620, 626, 632, 272, 278, 284, 290, 638, 644, 650, 656, 662, 668, 674, 362, 368, 374, 380, 680, 686, 692, 698, 704, 710, and 716, and variants having conservative modifications thereof.

[0254] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 560, 566, 578 and 590, and variants having conservative modifications thereof.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0255] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR3 selected from the group consisting of SEQ ID NOs: 3, 9, 15, 21, 513, 519, 525, 531, 537, 543, 549, 93, 99, 105, 111, 555, 561, 567, 573, 579, 585, 591, 183, 189, 195, 201, 597, 603, 609, 615, 621, 627, 633, 273, 279, 285, 291, 639, 645, 651, 657, 663, 669, 675, 363, 369, 375381, 681, 687, 693, 699, 705, 711, and 717, and variants having conservative modifications thereof.

[0256] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR3 selected from the group consisting of SEQ ID NOs: 561, 567, 579 and 591, and variants having conservative modifications thereof.

[0257] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 12; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 16, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 17, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 22, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 23, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 24; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 514, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 515, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 516; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 520, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 521, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 522;ATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 526, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 527, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 528; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 532, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 533, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 534; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 538, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 539, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 540; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 544, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 545, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 546; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 550, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 551, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 552.

[0258] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 520, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 521, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 522; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 526, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 527, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 528; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 538, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 539, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 540; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 550, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 551, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 552.

[0259] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprisesATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 96; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 100, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 101, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 102; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 106, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 108; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 112, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 113, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 114; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 556, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 557, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 558; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 562, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 563, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 564; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 568, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 570; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 574, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 575, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 576; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 580, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 581, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 582; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 586, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 587, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 588; orATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 592, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 593, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 594.

[0260] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 562, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 563, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 564; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 568, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 569, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 570; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 580, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 581, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 582; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 592, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 593, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 594.

[0261] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 184, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 185, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 186; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 190, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 191, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 192; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 196, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 197, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 198; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 202, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 203, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 204;ATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 598, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 599, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 600; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 604, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 605, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 606; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 610, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 611, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 612; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 616, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 617, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 618; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 622, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 623, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 624; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 628, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 629, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 630; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 635, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 636.

[0262] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 604, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 605, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 606; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 610, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 611, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 612;ATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 622, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 623, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 624; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 635, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 636.

[0263] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 274, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 275, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 276; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 280, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 281, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 282; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 286, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 287, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 288; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 292, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 293, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 294; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 640, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 641, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 642; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 646, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 648; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 652, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 653, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 654;ATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 658, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 659, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 660; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 664, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 665, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 666; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 670, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 671, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 672; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 676, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 677, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 678.

[0264] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 646, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 647, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 648; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 652, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 653, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 654; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 664, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 665, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 666; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 676, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 677, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 678.

[0265] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 364, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 365, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 366;ATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 370, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 371, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 372; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 376, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 377, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 378; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 382, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 383, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 384; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 682, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 683, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 684; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 688, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 689, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 690; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 694, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 695, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 696; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 700, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 701, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 702; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 706, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 708; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 712, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 713, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 714; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 718, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 720.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0266] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 688, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 689, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 690; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 694, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 695, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 696; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 706, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 707, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 708; or

[0267] a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 718, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 719, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 720.

[0268] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 16, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 17, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 18; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 106, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 107, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 108; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 196, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 197, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 198; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 286, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 287, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 288; or a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 376, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 377, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 378.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0269] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 1, 2, 3, 4, 5, and 6, respectively; b) SEQ ID NOs: 7, 8, 9, 10, 11, and 12, respectively; c) SEQ ID NOs: 13, 14, 15, 16, 17, and 18, respectively; d) SEQ ID NOs: 19, 20, 21, 22, 23, and 24, respectively; e) SEQ ID NOs: 511, 512, 513, 514, 515, and 516, respectively; f) SEQ ID NOs: 517, 518, 519, 520, 521, and 522, respectively; g) SEQ ID NOs: 523, 524, 525, 526, 527, and 528, respectively; h) SEQ ID NOs: 529, 530, 531, 532, 533, and 534, respectively; i) SEQ ID NOs: 535, 536, 537, 538, 539, and 540, respectively; j) SEQ ID NOs: 541, 542, 543, 544, 545, and 546, respectively; or k) SEQ ID NOs: 547, 548, 549, 550, 551, and 552, respectively.

[0270] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 517, 518, 519, 520, 521, and 522, respectively; b) SEQ ID NOs: 523, 524, 525, 526, 527, and 528, respectively; c) SEQ ID NOs: 535, 536, 537, 538, 539, and 540, respectively; or d) SEQ ID NOs: 547, 548, 549, 550, 551, and 552, respectively.

[0271] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 535, 536, 537, 538, 539, and 540, respectively.

[0272] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 547, 548, 549, 550, 551, and 552, respectively.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0273] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 91, 92, 93, 94, 95, and 96, respectively; b) SEQ ID NOs: 97, 98, 99, 100, 101, and 102, respectively; c) SEQ ID NOs: 103, 104, 105, 106, 107, and 108, respectively; d) SEQ ID NOs: 109, 110, 111, 112, 113, and 114, respectively; e) SEQ ID NOs: 553, 554, 555, 556, 557, and 558, respectively; f) SEQ ID NOs: 559, 560, 561, 562, 563, and 564, respectively; g) SEQ ID NOs: 565, 566, 567, 568, 569, and 570, respectively; h) SEQ ID NOs: 571, 572, 573, 574, 575, and 576, respectively; i) SEQ ID NOs: 577, 578, 579, 580, 581, and 582, respectively; j) SEQ ID NOs: 583, 584, 585, 586, 587, and 588, respectively; or k) SEQ ID NOs: 589, 590, 591, 592, 593, and 594, respectively.

[0274] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 559, 560, 561, 562, 563, and 564, respectively; b) SEQ ID NOs: 565, 566, 567, 568, 569, and 570, respectively; c) SEQ ID NOs: 577, 578, 579, 580, 581, and 582, respectively; or d) SEQ ID NOs: 589, 590, 591, 592, 593, and 594, respectively.

[0275] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 577, 578, 579, 580, 581, and 582, respectively.

[0276] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 589, 590, 591, 592, 593, and 594, respectively.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0277] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 181, 182, 183, 184, 185, and 186, respectively; b) SEQ ID NOs: 187, 188, 189, 190, 191, and 192, respectively; c) SEQ ID NOs: 193, 194, 195, 196, 197, and 198, respectively; d) SEQ ID NOs: 199, 200, 201, 202, 203, and 204, respectively; e) SEQ ID NOs: 595, 596, 597, 598, 599, and 600, respectively; f) SEQ ID NOs: 601, 602, 603, 604, 605, and 606, respectively; g) SEQ ID NOs: 607, 608, 609, 610, 611, and 612, respectively; h) SEQ ID NOs: 613, 614, 615, 616, 617, and 618, respectively; i) SEQ ID NOs: 619, 620, 621, 622, 623, and 624, respectively; j) SEQ ID NOs: 625, 626, 627, 628, 629, and 630, respectively; or k) SEQ ID NOs: 631, 632, 633, 634, 635, and 636, respectively.

[0278] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 601, 602, 603, 604, 605, and 606, respectively; b) SEQ ID NOs: 607, 608, 609, 610, 611, and 612, respectively; c) SEQ ID NOs: 619, 620, 621, 622, 623, and 624, respectively; or d) SEQ ID NOs: 631, 632, 633, 634, 635, and 636, respectively.

[0279] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 619, 620, 621, 622, 623, and 624, respectively.

[0280] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 631, 632, 633, 634, 635, and 636, respectively.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0281] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 271, 272, 273, 274, 275, and 276, respectively; b) SEQ ID NOs: 277, 278, 279, 280, 281, and 282, respectively; c) SEQ ID NOs: 283, 284, 285, 286, 287, and 288, respectively; d) SEQ ID NOs: 289, 290, 291, 292, 293, and 294, respectively; e) SEQ ID NOs: 637, 638, 639, 640, 641, and 642, respectively; f) SEQ ID NOs: 643, 644, 645, 646, 647, and 648, respectively; g) SEQ ID NOs: 649, 650, 651, 652, 653, and 654, respectively; h) SEQ ID NOs: 655, 656, 657, 658, 659, and 660, respectively; i) SEQ ID NOs: 661, 662, 663, 664, 665, and 666, respectively; j) SEQ ID NOs: 667, 668, 669, 670, 671, and 672, respectively; or k) SEQ ID NOs: 673, 674, 675, 676, 677, and 678, respectively.

[0282] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 643, 644, 645, 646, 647, and 648, respectively; b) SEQ ID NOs: 649, 650, 651, 652, 653, and 654, respectively; c) SEQ ID NOs: 661, 662, 663, 664, 665, and 666, respectively; or d) SEQ ID NOs: 673, 674, 675, 676, 677, and 678, respectively.

[0283] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 661, 662, 663, 664, 665, and 666, respectively.

[0284] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 673, 674, 675, 676, 677, and 678, respectively.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0285] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 361, 362, 363, 364, 365, and 366, respectively; b) SEQ ID NOs: 367, 368, 369, 370, 371, and 372, respectively; c) SEQ ID NOs: 373, 374, 375, 376, 377, and 378, respectively; d) SEQ ID NOs: 379, 380, 381, 382, 383, and 384, respectively; e) SEQ ID NOs: 679, 680, 681, 682, 683, and 684, respectively; f) SEQ ID NOs: 685, 686, 687, 688, 689, and 690, respectively; g) SEQ ID NOs: 691, 692, 693, 694, 695, and 696, respectively; h) SEQ ID NOs: 697, 698, 699, 700, 701, and 702, respectively; i) SEQ ID NOs: 703, 704, 705, 706, 707, and 708, respectively; j) SEQ ID NOs: 709, 710, 711, 712, 713, and 714, respectively; or k) SEQ ID NOs: 715, 716, 717, 718, 719, and 720, respectively.

[0286] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of a) SEQ ID NOs: 685, 686, 687, 688, 689, and 690, respectively; b) SEQ ID NOs: 691, 692, 693, 694, 695, and 696, respectively; c) SEQ ID NOs: 703, 704, 705, 706, 707, and 708, respectively; or d) SEQ ID NOs: 715, 716, 717, 718, 719, and 720, respectively.

[0287] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 703, 704, 705, 706, 707, and 708, respectively.

[0288] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 715, 716, 717, 718, 719, and 720, respectively.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0289] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 517, 518, 519, 520, 521 and 522, respectively; SEQ ID NOs: 523, 524, 525, 526, 527 and 528, respectively; SEQ ID NOs: 535, 536, 537, 538, 539, and 540, respectively; or SEQ ID NOs: 547, 548, 549, 550, 551, and 552, respectively.

[0290] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 535, 536, 537, 538, 539, and 540, respectively; SEQ ID NOs: 577, 578, 579, 580, 581, and 582, respectively; SEQ ID NOs: 619, 620, 621, 622, 623, and 624, respectively; SEQ ID NOs: 661, 662, 663, 664, 665, and 666, respectively; or SEQ ID NOs: 703, 704, 705, 706, 707, and 708, respectively.

[0291] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 523, 524, 525, 526, 527, and 528, respectively; SEQ ID NOs: 565, 566, 567, 568, 569, and 570, respectively; SEQ ID NOs: 607, 608, 609, 610, 611, and 612, respectively; SEQ ID NOs: 649, 650, 651, 652, 653, and 654, respectively; or SEQ ID NOs: 691, 692, 693, 694, 695, and 696, respectively.

[0292] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 547, 548, 549, 550, 551, and 552, respectively; SEQ ID NOs: 589, 590, 591, 592, 593, and 594, respectively; SEQ ID NOs: 631, 632, 633, 634, 635, and 636, respectively; SEQ ID NOs: 673, 674, 675, 676, 677, and 678, respectively; or SEQ ID NOs: 715, 716, 717, 718, 719, and 720, respectively.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0293] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 13, 14, 15, 16, 17, and 18, respectively; SEQ ID NOs: 103, 104, 105, 106, 107, and 108, respectively; SEQ ID NOs: 193, 194, 195, 196, 197, and 198, respectively; SEQ ID NOs: 283, 284, 285, 286, 287, and 288, respectively; or SEQ ID NOs: 373, 374, 375, 376, 377, and 378, respectively.

[0294] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 7, 8, 9, 10, 11, and 12, respectively; SEQ ID NOs: 97, 98, 99, 100, 101, and 102, respectively; SEQ ID NOs: 187, 188, 189, 190, 191, and 192, respectively; SEQ ID NOs: 283, 284, 285, 286, 287, and 288, respectively; or SEQ ID Nos: 367, 368, 369, 370, 371, and 372, respectively.

[0295] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 511, 512, 513, 514, 515, and 516, respectively; SEQ ID NOs: 553, 554, 555, 556, 557, and 558, respectively; SEQ ID NOs: 595, 596, 597, 598, 599, and 600, respectively; SEQ ID NOs: 637, 638, 639, 640, 641, and 642, respectively; or SEQ ID NOs: 679, 680, 681, 682, 683, and 684, respectively.

[0296] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 517, 518, 519, 520, 521, and 522, respectively; SEQ ID NOs: 559, 560, 561, 562, 563, and 564, respectively; SEQ ID NOs: 601, 602, 603, 604, 605, and 606, respectively; SEQ ID NOs: 643, 644, 645, 646, 647, and 648, respectively; orATTORNEY DOCKET NO. JBI6882WOPCT1 SEQ ID NOs: 685, 686, 687, 688, 689, and 690, respectively.

[0297] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises the heavy chain CDR1, the heavy chain CDR2, the heavy chain CDR3, the light chain CDR1, the light chain CDR2 and the light chain CDR3 comprising the amino acid sequence of SEQ ID NOs: 541, 542, 543, 544, 545, and 546, respectively; SEQ ID NOs: 583, 584, 585, 586, 587, and 588, respectively; SEQ ID NOs: 625, 626, 627, 628, 629, and 630, respectively; SEQ ID NOs: 667, 668, 669, 670, 671, and 672, respectively; or SEQ ID NOs: 709, 710, 711, 712, 713, and 714, respectively.

[0298] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 451, 453, 455, 457, 721, 723, 725, 727, 729, 731, or 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0299] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 455, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 456, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0300] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 451, 453, 455, 457, 721, 723, 725, 727, 729, 731, or 733; and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0301] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 723, 725, 729 or 733; and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 724, 726, 730 or 734.

[0302] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 729 and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 730.

[0303] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 733; and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 734.

[0304] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 455; and / or a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 456.

[0305] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence encoded by a nucleotide which can encode the VH sequence of SEQ ID NO: 451, 453, 455, 457, 721, 723, 725, 727, 729, 731, or 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / orATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain variable region (VL) comprising an amino acid sequence encoded by a nucleotide sequence which can encode the VL sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0306] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence encoded by a nucleotide which can encode the VH sequence of SEQ ID NO: 723, 725, 729 or 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a light chain variable region (VL) comprising an amino acid sequence encoded by a nucleotide sequence which can encode the VL sequence of SEQ ID NO: 724, 726, 730 or 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0307] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence encoded by a nucleotide sequence which can encode the VH sequence of SEQ ID NO: 451, 453, 455, or 457, 721, 723, 725, 727, 729, 731, or 733; and / or a light chain variable region (VL) comprising an amino acid sequence encoded by a nucleotide sequence which can encode the VL sequence of SEQ ID NO: 452, 454, 456, 458, 722, 724, 726, 728, 730, 732, or 734.

[0308] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region (VH) comprising an amino acid sequence encoded by a nucleotide sequence which can encode the VH sequence of SEQ ID NO: 723, 725, 729, or 733; and / or a light chain variable region (VL) comprising an amino acid sequence encoded by a nucleotide sequence which can encode the VL sequence of SEQ ID NO: 724, 726, 730 or 734.

[0309] In some embodiments, the anti-TCRγδ or antigen-binding fragment comprisesATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 451, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 452, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 453, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 454, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 455, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 456, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; or a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 457, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 458, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 721, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 722, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 723, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 724, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 725, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 726, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 727, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 728, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 729, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 730, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 731, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 732, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; or a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0310] In some embodiments, the anti-TCRγδ or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 723, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 724, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 725, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 726, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 729, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 730, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; or a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0311] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 451, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 452; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 453, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 454; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 455, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 456; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 457, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 458; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 721, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 722; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 723, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 724; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 725, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 726;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 727, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 728; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 729, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 730; a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 731, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 732; or a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 733, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 734.

[0312] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 723, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 724.

[0313] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 725, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 726.

[0314] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 729, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 730.

[0315] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 733, and a light chain variable region comprising an amino acid sequence of SEQ ID NO: 734.

[0316] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 451, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 452;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 453, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 454; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 455, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 456; or a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 457, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 458; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 721, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 722; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 723, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 724; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 725, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 726; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 727, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 728; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 729, and a light chain CDR1,ATTORNEY DOCKET NO. JBI6882WOPCT1 a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 730; a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 731, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 732; or a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 733, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 734.

[0317] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 723, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 724.

[0318] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 725, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 726.

[0319] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 729, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 730.

[0320] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprisesATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 733, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region comprising an amino acid sequence of SEQ ID NO: 734.

[0321] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 451, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 452, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 453, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 454, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 455, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 456, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 457, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded byATTORNEY DOCKET NO. JBI6882WOPCT1 the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 458, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 721, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 722, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 723, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 724, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 725, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 726, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 727, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 728, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 729, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 730, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 731, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 732, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; or a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0322] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 723, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 724, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0323] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 725, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 726, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0324] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 729, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 730, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0325] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 733, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 734, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0326] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 451, and a light chainATTORNEY DOCKET NO. JBI6882WOPCT1 variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 452; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 453, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 454; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 455, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 456; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 457, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 458; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 721, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 722; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 723, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 724; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 725, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 726; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 727, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 728;ATTORNEY DOCKET NO. JBI6882WOPCT1 a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 729, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 730; a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 731, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 732; or a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 733, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 734.

[0327] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 723, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 724.

[0328] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 725, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 726.

[0329] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 729, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 730.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0330] In some embodiments, the anti-TCRγδ antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VH sequence of SEQ ID NO: 733, and a light chain variable region comprising an amino acid sequence encoded by the nucleotide sequence which can encode the VL sequence of SEQ ID NO: 734.

[0331] In various embodiments, the anti-TCRγδ antibody or antigen-binding fragment does not have non-specific binding to Immunoglobulin G (IgG). In some embodiments, the anti- TCRγδ antibody or antigen-binding fragment does not bind to the constant region of Immunoglobulin G (IgG).

[0332] The specific antibodies defined by CDR and / or variable domain sequence discussed in the above paragraphs may include additional modifications.

[0333] The TCRγδ-specific antibodies or antigen-binding fragments described herein include variants having single or multiple amino acid substitutions, deletions, or additions that retain the biological properties (e.g., binding affinity or immune effector activity) of the described TCRγδ- specific antibodies or antigen-binding fragments. In the context of the present disclosure the following notations are, unless otherwise indicated, used to describe a mutation; i) substitution of an amino acid in a given position is written as e.g. S228P which means a substitution of a Serine in position 228 with a Proline; and ii) for specific variants the specific three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue. Thus, the substitution of Serine for Arginine in position 228 is designated as: S228P, or the substitution of any amino acid residue for Serine in position 228 is designated as S228P. In case of deletion of Serine in position 228 it is indicated by S228*. The skilled person may produce variants having single or multiple amino acid substitutions, deletions, or additions.

[0334] These variants may include: (a) variants in which one or more amino acid residues are substituted with conservative or nonconservative amino acids, (b) variants in which one or more amino acids are added to or deleted from the polypeptide, (c) variants in which one or more amino acids include a substituent group, and (d) variants in which the polypeptide is fused with another peptide or polypeptide such as a fusion partner, a protein tag or other chemical moiety, that may confer useful properties to the polypeptide, such as, for example, an epitope for an antibody, a polyhistidine sequence, a biotin moiety and the like. Antibodies or antigen-bindingATTORNEY DOCKET NO. JBI6882WOPCT1 fragments described herein may include variants in which amino acid residues from one species are substituted for the corresponding residue in another species, either at the conserved or nonconserved positions. In other embodiments, amino acid residues at nonconserved positions are substituted with conservative or nonconservative residues. The techniques for obtaining these variants, including genetic (deletions, mutations, etc.), chemical, and enzymatic techniques, are known to persons having ordinary skill in the art.

[0335] Amino acid substitutions may be conservative, by which it is meant the substituted amino acid has similar chemical properties to the original amino acid. A skilled person would understand which amino acids share similar chemical properties. For example, the following groups of amino acids share similar chemical properties such as size, charge and polarity: Group 1 - Ala, Ser, Thr, Pro, Gly; Group 2 - Asp, Asn, Glu, Gln; Group 3 - His, Arg, Lys; Group 4 - Met, Leu, Ile, Val, Cys; Group 5 - Phe, Thy, Trp.

[0336] The TCRγδ-specific antibodies or antigen-binding fragments described herein may embody several antibody isotypes, such as IgM, IgD, IgG, IgA and IgE. In some embodiments the antibody isotype is IgG1, IgG2, IgG3, or IgG4 isotype, preferably IgG1 or IgG4 isotype. In some embodiments the antibody isotype is IgA1 or IgA2. Antibody or antigen-binding fragment thereof specificity is largely determined by the amino acid sequence, and arrangement, of the CDRs. Therefore, the CDRs of one isotype may be transferred to another isotype without altering antigen specificity. Alternatively, techniques have been established to cause hybridomas to switch from producing one antibody isotype to another (isotype switching) without altering antigen specificity. Accordingly, such antibody isotypes are within the scope of the described antibodies or antigen-binding fragments.

[0337] The antibody or antigen-binding fragment can have any level of affinity or avidity for a TCRγδ heterodimer. In some embodiments, the antibody or antigen-binding fragment may bind the TCRγδ heterodimer with a range of affinities (KD). In various embodiments, the antibody or antigen-binding fragment binds to the TCRγδ heterodimer with high affinity, for example, with a KD equal to or less than about 10−7M, such as but not limited to, 1-9.9 (or any range or value therein, such as 1, 2, 3, 4, 5, 6, 7, 8, or 9)×10−8M, 10−9M, 10−10M, 10−11M, 10−12M, 10−13M, 10−14M, 10−15M or any range or value therein, as determined by, e.g., surface plasmon resonance or the Kinexa method, as practiced by those of skill in the art. One example affinity is equal to or less than 1×10−8M. Another example affinity is equal to or less than 1×10−9M.ATTORNEY DOCKET NO. JBI6882WOPCT1

[0338] Methods of testing antibodies for the ability to bind to the target TCRγδ heterodimer or any portion thereof are known in the art and include any antibody-antigen binding assay, such as, for example, radioimmunoassay (RIA), Western blot, enzyme-linked immunosorbent assay (ELISA), immunoprecipitation, and competitive inhibition assays.

[0339] Also disclosed are isolated polynucleotides that encode the antibodies or antigen- binding fragments that specifically bind to a TCRγδ heterodimer. The isolated polynucleotides capable of encoding the heavy chain (HC) sequence, light chain (LC) sequence, heavy chain variable region (VH) sequence, and / or light chain variable region (VL) sequence may be included on the same, or different, vectors to produce antibodies or antigen-binding fragments. Polynucleotide sequences that may encode the HC, LC, VH and / or VL of an anti-TCRγδ antibody described herein, or an antigen-binding fragment thereof, are also within the scope of the present disclosure.

[0340] In some embodiments, an isolated polynucleotide encoding an anti-TCRγδ antibody or antigen-binding fragment comprises a nucleotide sequence which can encode a heavy chain sequence corresponding to HC1- 22 set forth in Table 7, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a nucleotide sequence which can encode a light chain sequence corresponding to LC1-22 set forth in Table 7, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0341] In some embodiments, an isolated polynucleotide encoding an anti-TCRγδ antibody or antigen-binding fragment comprises a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH1-22 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; and / or a nucleotide sequence which can encode a light chain variable region sequence corresponding to VL1-22 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto.

[0342] In some embodiments, an isolated polynucleotide encoding an anti-TCRγδ antibody or antigen-binding fragment comprisesATTORNEY DOCKET NO. JBI6882WOPCT1 a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH1 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a nucleotide sequence which can encode a light chain variable region corresponding to VL1 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH2 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a nucleotide sequence which can encode a light chain variable region sequence corresponding to VL2 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH3 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a nucleotide sequence which can encode a light chain variable region sequence corresponding to VL3 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH4 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a nucleotide sequence which can encode a light chain variable region sequence corresponding to VL4 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto; a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH5 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a nucleotide sequence which can encode a light chain variable region sequence corresponding to VL5 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto;ATTORNEY DOCKET NO. JBI6882WOPCT1 a nucleotide sequence which can encode a heavy chain variable region sequence corresponding to VH6 set forth in Table 6, or a sequence having at least 80%, 85%, 90%, preferably 95% or more, such as 95%, 96%, 97%, 98%, or 99% identity thereto, and a nucleotide sequence which can encode a light chain variable region sequence corresponding to VL6 set forth in Table 6, or a seq...

Claims

1. ATTORNEY DOCKET NO. JBI6882WOPCT1 CLAIMS What is claimed is:

1. A serum-free, xeno-free, and feeder-free method for selectively activating and expandinghuman γδ T cells comprising: (a) contacting the γδ T cells with an isolated antibody or antigen-binding fragment;(b) culturing the γδ T cells in cell culture medium comprising a cytokine selected fromIL-2, IL-7, IL-12, IL-15, IL-18, IL-21, IL-22, IL-27, and TGFβ, and combinations thereof; wherein the cell culture medium further comprises a serum substitute.

2. The method of claim 1, wherein the γδ T cells are derived from induced pluripotent stemcells (iPSCs) and / or from peripheral blood mononuclear cells (PBMCs).

3. The method of any one of claims 1-2, wherein the isolated antibody or antigen-bindingfragment binds to a region of a TCRγδ heterodimer in step (a).

4. The method of claim 2 or 3, wherein the iPSC-derived γδ T cells and / or the PBMC-derived γδ T cells are engineered to express a chimeric antigen receptor (CAR).

5. The method of any one of claims 1-4, wherein the iPSC-derived γδ T cells are engineeredto express a CAR prior to step (a) or the PBMC-derived γδ T cells are engineered to express a CAR after step (a).

6. The method of any one of claims 4-5, wherein the CAR-engineered γδ T cells areexposed to cell culture medium comprising IL-21 and IL-15 for 2 days.

7. The method of any one of claims 1-6, wherein the isolated antibody or antigen-bindingfragment binds to Vγ9, Vδ2, Cγ1, Cγ2 or Cδ domain of the TCRγδ heterodimer expressed by human γδ T cells and acts as a TCR agonist and triggers TCR-coupled signaling pathways leading to T cell activation.

8. The method of any one of claims 1-7, wherein the serum substitute is Cell-ViveTM T-NKxeno-free serum substitute.

9. The method of any one of claims 1-8, wherein the serum substitute has a concentration of5% to 10%.

10. The method of claim 9, wherein the serum substitute concentration is 10%.

11. The method of any one of claims 1-10, wherein the isolated antibody or antigen-bindingfragment has a concentration of about 0.5 to about 10 µg / mL. ATTORNEY DOCKET NO. JBI6882WOPCT112. The method of claim 11, wherein the isolated antibody or antigen-binding fragment has aconcentration of 2.5 µg / mL.

13. The method of any one of claims 1-12, wherein contacting the γδ T cells with an isolatedantibody or antigen-binding fragment has a duration of about 0.5 to about 3.5 days.

14. The method of claim 13, wherein contacting the γδ T cells with an isolated antibody orantigen-binding fragment has a duration of 2 days.

15. The method of any one of claims 1-14, wherein the γδ T cells are seeded in step (a) atabout 1 x 106cells / mL to about 0.1 x 106cells / mL.

16. The method of claim 15, wherein the γδ T cells are seeded at 0.5 x 106 cells / mL.

17. The method of any one of claims 1-16, wherein the γδ T cells are seeded in step (b) atintervals in descending cell density.

18. The method of any one of claims 1-17, wherein the isolated antibody or antibodyfragment is listed in any of Tables 1-7, or is derived from an antibody or antibody fragment listed in any of Tables 1-7.

19. The method of any one of claims 1-18 wherein the isolated antibody is VG9B1244,VG9B1254, VG9B1348 or VG9B1701.

20. A serum-free, xeno-free, and feeder-free system for selectively activating and expandinghuman γδ T cells comprising: (a) a means for stimulating expansion of the γδ T cells or providing a means forstimulating expansion of the γδ T cells; (b) a cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15,IL-18, IL-21, IL-22, IL-27, and TGFβ, and combinations thereof or providing a cell culture medium comprising a cytokine selected from IL-2, IL-7, IL-12, IL-15, IL 18, IL-21, IL-22, IL- 27, and TGFβ, and combinations thereof; wherein the cell culture medium further comprises a serum substitute.

21. The system of claim 20, wherein the γδ T cells are derived from induced pluripotent stemcells (iPSCs) and / or from peripheral blood mononuclear cells (PBMCs).

22. The system of any one of claims 20-21, wherein means for stimulating the expansion ofthe γδ T cells comprises an isolated antibody or antigen-binding fragment that binds to a region of a TCR heterodimer. ATTORNEY DOCKET NO. JBI6882WOPCT123. The system of any one of claims 20-22, wherein the iPSC-derived γδ T cells and / or thePBMC-derived γδ T cells are engineered to express a CAR.

24. The system of claim 23, wherein the iPSC-derived γδ T cells and / or the PBMC-derivedγδ T cells are engineered to express a CAR prior to activation and expansion.

25. The system of any one of claims 20-24, wherein the iPSC-derived γδ T cells areengineered to express a CAR prior to step (a) or the PBMC-derived γδ T cells are engineered to express a CAR after step (a).

Images